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MINING THE FRANCISELLA TULARENSIS PROTEOME FOR VACCINE CANDIDATES 
 
Based on methodologies developed for the identification of T cell antigen of other 
intracellular bacterial pathogens, a proteomic approach was applied for the elucidation of T cell 
antigens of Francisella tularensis (Covert, 2001).  Specifically, subcellular components 
(membrane and soluble) of F. tularensis LVS were resolved by size using preparative SDS-
PAGE and fractions collected using a whole gel elution technique.  A total of 16 soluble and 19 
membrane-sized fractions were produced, each of which were assessed for antigen reactivity 
based on the ability to elicit IFN-γ from splenocytes of F. tularensis LVS-infected mice.  Of 
these 35 preparative SDS-PAGE fractions, seven yielded a dominant T cell response.  These 
seven fractions were further investigated using tandem mass spectrometry (MS/MS) to identify 
individual proteins in each immunodominant fraction.  A total of 40 and 31 proteins were 
identified with greater than 95% confidence from the immunodominant membrane and soluble 
fractions, respectively.  Further, MS/MS analysis of different protein quantities (2.5 µg to 10 µg) 
allowed for identification of the most abundant proteins in each fraction, thus focusing the 
number of possible proteins to nine proteins of interest.  These data provide the basis for 
production of recombinant proteins and further immunological evaluations to select suitable 
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Tularemia is a resulting disease through infection by the bacterium Francisella 
tularensis, against which, there is no licensed vaccine (36, 91).  Delayed treatment can result in 
debilitating illness and in some cases, death (48).  Cutaneous infection with less than 10 colony 
forming units (CFU) of the subspecies tularensis make this bacterium one of the most infectious 
pathogens in humans and it can infect over 250 mammalian species (110, 140, 141).  Water-
borne transmission from F. tularensis subspecies holarctica is frequently reported, whereas this 
has yet to be shown as a reservoir for the subspecies tularensis (14, 15, 19, 47).  Human-to-
human transmission has not been documented, but F. tularensis can be transmitted to humans via 
insect vectors, inhalation, consumption, or direct contact with the bacterium from other infected 
mammals (47, 110, 123).  F. tularensis has been previously weaponized and has the potential of 
being used as a biowarfare agent (36, 42, 44).  This potential threat has increased research on 
tularemia, and thus increased the number of laboratory personnel working closely with this 
bacterium (36).  While a vaccine for tularemia may not be widely used, it could be effectively 
administered to specific sections of our society such as the military, first responders, and 
laboratory workers.  Additionally, the development of an effective vaccine could minimize, or 
eliminate the need for rapid therapeutic intervention in high-risk populations.  The only vaccine 
against tularemia is not licensed for human use and the US Food and Drug Administration 
(FDA) has revoked its investigative new drug (IND) status due to critical knowledge gaps in 
mechanism of attenuation, ability to cause virulence in mice, immunogenic variability, and 
inability to establish levels of herd immunity (38, 48, 52, 55, 110, 140).  The current vaccine 
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needs to be updated and improved to provide more consistent protection against infection by F. 
tularensis (36, 144).  
 F. tularensis was initially isolated in 1911 in Tulare County, California, by Dr. George 
McCoy et al. (109) from ground squirrels with a plague-like illness.  Originally suspected to be 
caused by Yersinia pestis, this study established that Bacterium tularense (original spelling) was 
instead, the cause of the disease (109).  The bacterium was grouped in the family Pasturella, and 
later, Dr. Edward Francis was able to link it to diseases named deer-fly fever, rabbit fever, and 
rancher’s fever.  In 1921, due to Dr. Francis’ continual research efforts, Pasturella tularensis was 
re-named, Francisella tularensis, in his honor (133). 
Francisella tularensis is an aerobic, Gram-negative, intracellular pathogen usually found 
as single pleomorphic cells, that commonly exhibit a coccobacilli-shape (160).  It is part of the 
family Francisellaceae, genus Francisella and species tularensis.  F. tularensis can further 
divided into three subspecies (Fig. 1.1).  Of these, subsp. tularensis and subsp. holarctica, are 
associated most with the human disease whereas, subsp. mediasiatica is less likely to cause 
human disease.  Predominantly found in North America, subsp. tularensis (Type A) is classified 
as a Category A agent by National Institute of Allergy and Infectious Diseases (NIAID) and the 
Center for Disease Control and Prevention (CDC) (122).  Francisella tularensis subsp. holartica 
(Type B) is mainly found in Europe, North America, Siberia, and the Far East and is of similar 
virulence to that of subspecies mediasiatica encompassing most central Asian strains (26, 52, 54, 
56, 90, 96).  The live vaccine strain for F. tularensis is derived from F. tularensis subsp. 
holarctica and can cause lethal infections in some mouse strains (122).  F. novicida, and F. 
philomiragia are opportunistic pathogens in immunocompromised humans and otherwise 






Figure 1.1 Phylogeny of Francisellacaea.  Figure adapted from Pathosystems Resource 
Integration Center (PATRIC): 
http://patricbrc.vbi.vt.edu/portal/portal/patric/Taxon?cType=taxon&cId=262  
 
The greatest risk of contracting the disease lies with those who come in close contact 
with infected animals and vectors, such as hunters, lawn-care workers, farmers, laboratory-
workers, veterinarians, and hikers (124, 152).  A highly publicized account of tularemia brought 
this disease back to the forefront of human medicine in the United States in 2001, when an 
outbreak occurred in Martha’s Vineyard, Massachusetts.  Fifteen confirmed cases resulting in 
one death from “lawnmower tularemia”, as it was later termed, took place after a lawn-care 
worker operating a brush-mower, drove over a rabbit, possibly causing the bacteria to become 
aerosolized and inhaled by the workers in the vicinity (62).   
Outside of natural infection, many countries, including The United States and Japan, 
considered weaponizing tularemia during the 1930’s and 1940’s (77).  During World War II, 
there was speculation that Russia purposely deployed F. tularensis as a bioweapon, although 
they reported these cases as a natural outbreak (4, 77, 95).  During the 1972 Convention on the 
Prohibition of Production, Development, and Stockpiling of Bacteriological (Biological) and 
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of offensive programs involving biological weapons and toxins was ratified (30).  After the 
cessation of offensive biological weapons research and development, the U.S. focused on 
defensive research against possible tularemia attacks.  Recent estimations of the economic 
impact of a bioterrorist attack involving tularemia is 3.8 to 5.4 billion U.S. dollars for every 
100,000 persons infected (95).  Vaccine research for the prevention of tularemia has the potential 
to thwart loss of life and minimize economic loss in the event of an attack or due to natural 
exposure. 
Clinical forms of tularemia can vary greatly, depending on the mode of transmission.  
Table 1.1 explains the different modes of transmission and risk factors for each clinical form of 
the disease.  
Table 1.1 Modes of transmission and risk factors of tularemia 




contaminated dust (157)  
Farmers may become infected with this 
form of tularemia due to handling of hay 
contaminated with infected mouse 
excrement (157) 
Oculoglandular Infection via the  
conjunctiva of the eye 
Touching the eye after contact with 
contaminated substance (150) 
Oropharyngeal Ingestion  Contaminated food or water (83) 
Typhoidal Unknown route of 
infection (110, 123) 
 
Ulceroglandular Bite from a recently-
infected vector (161) 
Flea, deer tick, rabbit tick, mosquito, and 
biting flies (161) 
Glandular Direct contact with 
infected tissue 
Hunters occasionally contract the disease 
after skinning and cleaning wild hare 
 
Respiratory tularemia, caused by F. tularensis subsp. tularensis, is the most lethal form 
of the disease, with as few as 25 organisms causing infection (110, 159).  According to 
McCrumb, without treatment 40 - 60% of patients who developed respiratory tularemia, died of 





the disease (110, 129).  Ulceroglandular tularemia is the most frequently reported form of the 
disease; where 12-15% of all F. tularensis infected individuals develop pneumonia, and only 3% 
of non-treated non-respiratory cases result in death (60, 110).   
Disease pathogenesis begins with the entrance of the pathogen into the host, through one 
of the routes listed in Table 1.1.  The incubation period is between 3-6 days (60, 87) after which, 
flu-like symptoms usually occur suddenly and include fever, chills, malaise, lymphadenopathy, 
and headache (87).  The bacterium is spread via the lymphatics to regional lymph nodes and can 
result in plague-like bubos on the infected individual (90, 151).  From the nodes, the bacterium 
disseminates throughout the body and localizes mainly to the spleen, liver, and lymph nodes, but 
can also be found in the kidneys, intestine, and central nervous system, leading to death within 5-
10 days (53, 56).  
One reason for F. tularensis’ virulence is in its evasion of host immunity via escape from 
the phagosome and quiet replication within the cytosol of the phagocytic cell.  During 
conventional phagocytosis, a bacterium can be taken up by a macrophage into a phagosome and 
can be killed quickly when the lysosome fuses with the phagosome.  In reference to F. 
tularensis, once the bacterium is taken up in the macrophage, either by the pseudopodal loops or 
through conventional phagocytosis, it does not cause an NO oxidative burst.  Instead it enters a 
vacuole, which does not bind with a lysosome, thus allowing time for F. tularensis to disrupt the 
phagosomal membrane and escape into the host cell cytoplasm where replication ensues (33).  It 
was shown by Checroun et al. that F. tularensis could escape the phagosome as early as 20 min 
and re-enter the endocytic pathway to accumulate and form Francisella containing vacuoles 
(FCV) where it can thrive from 4 - 20 h (28).  Goloviov et al. showed that IglC production (23-





kDa) was important in replication within the macrophage, for without the iglC gene, F. 
tularensis had impaired replication and was attenuated in the mouse model (72).   
A unique feature recently uncovered by Santic et al. (138) is the mechanism by which the 
macrophage can engulf F. tularensis with asymmetric pseudopod loops.    Clemens et al. (32) 
determined that this unique macrophage uptake required active complement component C3 in 
serum.  The authors determined that formalin-killed F. tularensis was taken up by macrophages 
through the pseudopod loops, thus indicating the molecules that trigger the uptake into 
macrophages are pre-formed and do not require metabolic activity by the bacteria (32).  In 
addition, they showed that heat-treated and protease-treated F. tularensis did not affect the 
formation of pseudopod loops for the uptake of the bacteria.  This is important in vaccine 
development, because it shows that the molecules that trigger the uptake are heat resistant and 
protease resistant, thus indicating lipopolysaccharides as a possible ligand-mediating uptake 
mechanism (32).  The LPS of F. tularensis is discussed further in section 1.6.   
Current treatment of tularemia is limited to antibiotic therapy, which is most effective 
during the initial onset of the disease.  Up until 1995, streptomycin, an aminoglycoside, was the 
preferred antibiotic due to higher success rate of around 97% without relapse (57, 132).  
Gentamicin, another protein synthesis-inhibiting aminoglycoside, has a slightly lower success 
rate of 86% and relapse rate of about 6%, but with fewer side-effects and thus has become the 
preferred method of treatment for tularemia (78).  Tetracycline had an 88% success rate and 
chloramphenicol had a 77% success rate and both work by inhibiting protein synthesis.  
However, they have been shown to have higher relapse rates of 12% and 21% respectively, and 






and norfloxacin, work by inhibiting DNA synthesis and have also recently been shown to work 
well in treatment of tularemia without relapse (158).  Among the drug therapies used during a 
1997 tularemia outbreak in Spain, ciprofloxacin was shown to be a very good alternative to 
aminoglycosides and tetracycline therapy (126).   
Due to the generic flu-like symptoms, tularemia is typically not recognized until the 
patient is hospitalized, and although there are treatment options for tularemia, delay in these 
treatments could lead to relapse, increased severity of disease and possible death (47, 71).  Thus, 
there is also a need for more advanced diagnostics that decrease the time from initial symptoms 
to the identification of F. tularensis as the etiological agent of disease.  This would dramatically 
influence the administration of effective antibiotics.   
Prior to treatment of the disease, one must know what is being treated and this is done 
through a variety of diagnostic methods.  In 1965, White et al. suggested the most “satisfactory” 
way to diagnose P. tularensis infection was through bacteriological culture (169).  This method 
requires special media, poses risk to the laboratory workers and takes time for growth (169).  To 
achieve a quicker result, White et al. applied a technique by Coons and Kaplan, using a 
fluorescein-tagged antibody detection technique (original spelling) (39, 169).  The bacterium can 
be successfully identified from the blood, ulcers, conjunctival exudates, pleural fluid, sputum, 
gastric aspirates, and pharyngeal exudates using the fluorescein-tagged antibody technique, 
antigen detection, PCR, or enzyme-linked immunoassays (16, 18, 48, 94, 156).  Whereas these 
are the quickest ways to detect the pathogen, due to the hazards posed by this pathogen, only 
specific state and national laboratories are allowed to run these tests (48, 94).  For retroactive 






serum antibody titer test needs to have a 4-fold change in titer, which takes at least 10 days, by 
which time it may be too late for treatment of the patient (18, 48). 
“The key event that triggers the immune response is the immune system sensing a 
vaccine or microbe (128).”  This statement is the basis for the studies included in this thesis.  
One of the key virulence factors of F. tularensis is its ability to evade the immune system.  It 
infects the host cells and quietly replicates, suppressing the innate immune response or 
inflammatory response long enough to replicate to a point where it is difficult for the body to 
clear the infection (162).  Only when we can uncover key antigens that trigger active killing or 
suppression of the F. tularensis infection and illicit a strong memory immune response for these 
antigens, will we be able to say that we have created a successful vaccine candidate for 
tularemia.   
Vaccine research of F. tularensis began in the 1930’s in Russia.  By the 1940’s they had 
attenuated Francisella tularensis subsp. holartica by multiple passages of the bacterium through 
river rats (52, 163).  In 1956, United States Army Medical Research Institute of Infectious 
Diseases (USAMRIID) received the attenuated strain during a medical exchange and refined it 
into the live vaccine strain (LVS) (1, 52).  Eigelsbach et al. noted, when developing the live 
attenuated vaccine, two colony phenotypes were apparent when viewed with an oblique light-
source (52).  These colonies were the virulent, blue colonies or less virulent, gray colonies (52).  
For the vaccine to be effective, a ratio of at least 20% blue colonies to 80% gray colonies had to 
comprise the LVS inoculums (52).   
Eigelsbach et al. stated that the rate at which population phenotypes change in B. 






liquid media, without shaking, for a prolonged timeframe (51).  Further studies into immune 
response and growth conditions of Francisella have uncovered another virulence variant, ACV 
(activating variant).  The ACV variant, which arose from high density cultures, has uniquely 
been shown by Carlson et al. to induce increased pro-inflammatory cytokines such as TNF-, 
IL-1, IL-12p40, reiterating the fact that culture conditions must be optimal for Francisella, in 
order to have the most beneficial vaccine (23).  
Experimental models for studying potential vaccine candidates and the pathogenesis of 
tularemia include: non-human primates, rats, mice, guinea pigs, rabbits, and in the past, humans 
(107).  In a retrospective study at Fort Detrick, Maryland, LVS vaccination decreased the 
incidence of respiratory tularemia in humans from 5.7 to 0.27 cases per 1,000 subjects (22).  The 
incidence of ulceroglandular tularemia in the same population remained unchanged, but the 
symptoms were less severe in those receiving the vaccine  (22).  Inmates at the Maryland House 
of Correction were used in a study conducted on the efficacy of an aerosolized route for LVS 
vaccination versus that of a cutaneous route (87).  The investigators of this study came to the 
conclusion that inhalation of aerosolized LVS was not as protective as the parenteral injection 
method, but that inhalation should not be disregarded as a means for vaccination (22, 87).  
Whereas the human model was the most efficient for targeting new therapeutics and vaccines, 
the ability to extrapolate data from other animal models has allowed scientists to move away 
from human volunteers as models (107).   
The three types of vaccines commonly utilized to protect against infectious diseases 
consist of living microorganisms, killed microorganisms, or subunits of microorganisms (Table 
1.2).  The original live, attenuated Francisella vaccine (LVS) produced long-lasting humoral and 





cellular responses, and required few doses to be effective.  However, there is a risk that LVS 
might revert to a virulent form in the host due to its unknown basis of attenuation (136).  This 
type of vaccine cannot be given to immune-compromised individuals or children, and there is a 
risk of variable protection from batch-to-batch, due to the organism’s ability to randomly switch 
phenotypes and thus change immunogenicity (136).  The LVS vaccine does not confer complete 
protection, but did drastically decrease the amount of respiratory, but not ulceroglandular-type, 
infections in laboratory personnel after its introduction (22).  When compared to killed bacteria, 
Tärnvik suggests that the live bacteria are processed more efficiently by phagocytic cells and 
thus more of the immunogen circulates in the body for a more robust immune response (159).   
Bakshi et al. created a mutant strain of F. tularensis LVS, in an attempt to attenuate it 
further and genetically define the mutation for use as a safer more efficacious vaccine over LVS.  
F. tularensis contains superoxide dismutases (SODs) that play an important role during 
phagocytosis to cause dismutation of superoxide radicals created during respiratory burst.  
Without the iron-containing SOD, the mutated F. tularensis LVS (sodBFt), became more 
sensitive to oxidative stress.  The vaccination of mice with sodBFt had a significant, protective, 




 T cells for 




 T cells.  Bakshi et al. showed the 
sodBFt mutant as a vaccine candidate against respiratory tularemia with enhanced protective 
efficacy over LVS (11). 
Table 1.2  Comparison of vaccines 
Advantage / Disadvantage (61, 136) Subunit  Killed  Live  
Reversion Risk  No  No  Yes  
Specific Antigen Target  Yes  No  No  
Multiple Doses Yes  Yes  Fewer  
Variable Production  No  Yes  Yes  
Targeted Immune Response via Adjuvant  Yes  Yes/No  No  





Vaccines containing killed bacteria do not have a risk of reversion, and also have fewer 
possible side-effects than vaccines containing live bacterial cells (136).  There are some 
drawbacks to using killed vaccines, such as a requirement of multiple doses for continual 
protection, as well as the cost of manufacturing the vaccine , and the variable immunogenicity 
that is possible because of the methods used to kill the bacterium (136).  A “killed-vaccine” for 
tularemia was tested in the early 1930’s, but its efficacy was questionable, and some patients 
incurred severe local reactions at the site of vaccination (64, 140, 141).  The F. tularensis 
“killed-vaccine” tested by Foshay, needed to be re-administered multiple times throughout the 
year for the patient to benefit (64).  The immunized patients that were not fully protected by the 
vaccine however, suffered less severe symptoms from subsequent infection (64).  In another 
study, a control group of non-human primates received the vaccine and had similar infectivity 
rates as the challenged group (40). 
Subunit vaccines normally consist of important pathogen genes, proteins or 
polysaccharides that are presented to the immune system.  Unlike killed vaccines, a protein 
subunit vaccine is delivered in an immune-stimulating adjuvant formulation, that can stimulate 
long-lasting cellular and humoral immunity (76, 136), and it is safer than a live vaccine, because 
it poses no risk for reversion when introduced into a host.  Further, specific immune responses 
can be targeted depending on the choice of adjuvant.  However, there is a possibility for adverse 
reactions to the adjuvant, and the vaccination may require multiple doses for full protection 
(135).  F. tularensis proteins with the molecular masses of 61, 37, 32, and 17 kDA have been 
shown in previous studies to stimulate T cell proliferation in human subjects.  Unfortunately, 
1.4.2 Killed vaccines 





when used in protective studies, these proteins and others, failed to demonstrate complete 
protection in the mouse or human model (137, 146, 154, 155).  In another study, a proven T cell 
reactive protein, Tul4, was shown to only induce a minimal protective response in mice through 
subcutaneous immunization (70).  Subunit vaccines containing outer membrane proteins have 
been shown by Huntley et al. to be substantially protective against virulent type A F. tularensis, 
thus showing, at the very least, proof of concept for the use of a subunit vaccine (89). 
An alternative to outer membrane isolated from whole cells is the outer membrane 
vesicles (OMV) secreted by F. tularensis LVS.  The OMV can contain protein components from 
the outer membrane, periplasm and cytoplasm as well as cellular enzymes, which can aid in the 
pathogenic virulence in multiple ways (101).  In study by Pierson et al., OMVs were isolated 
from F. novicida and administered in their natively-folded state, as an intranasal vaccine, 
resulting in a significant survival rate when compared to the naïve mice (127).  
The immune response can be broken down into innate and adaptive immunity.  The 
innate immune system is the first line of defense against the pathogen, non-specific, without a 
memory response, and informs the adaptive response about the type of pathogens it encounters 
via cytokine secretions (43).  In F. tularensis, the innate system has been shown to be helpful in 
the primary line of defense against tularemia, however, it alone does not provide for long term 
protection of infected mice (36).  The adaptive immune system evolved from innate immune 
mechanisms and it does not work properly without interaction with the innate processes (43).   
 The initiation of the adaptive immune response requires the interaction of antigen 
presenting cells (APCs) with T or B cells, through recognition of antigen-bound receptors by 
specific T and B cell receptors (2).  When a foreign antigen is engulfed by an APC, it is 





processed and displayed on the surface of the APC by a MHC class II molecule (2).  If the 
antigen escapes to the cytosol of the APC or if a nucleated cell is invaded, it will be processed by 
a proteosome in the cytosol and displayed on the surface bound to an MHC class I molecule (2).  
These interactions, are regulated by cytokines and can result in either a humoral or cellular 
immune response over the course of 2-3 days (2).     
The humoral response involves antibody production and is mediated by B-lymphocytes 
that have B cell receptors (BCR’s) which can bind directly to epitopes on antigens (2).  During a 
humoral response, the B cell receptors on the B cell can bind epitopes on invading pathogens, 
then engulf and process them through an MHCII,  for display of the bound antigen onto its 
surface (2).  A circulating T4-lymphocyte, with a complementary T cell receptor and CD4+ 
molecule, can recognize this activated, surface MHCII-bound antigen and begin releasing 
interleukins that either aid in, or block, B cell differentiation into memory B cells or antibody-
secreting plasma cells (2).  Humoral immunity can play a part in protection against Francisella, 
as indicated by a rise in antibody levels in human volunteers after vaccination with F. tularensis 
LVS (166). 
The cellular response is mediated by T-lymphocytes with T cell receptors (TCR’s) that 
only recognize major histocompatibility complex (MHC)-bound antigens presented on APCs (2).  
In a cellular response, CD4
+
 T cells play an important role and recognize exogenous antigens and 
CD8
+ 
T cells recognize endogenously-processed peptides via MHCI (6).  In order to produce a 
CD4
+
 T cell response, the  APCs are first primed by engulfing the antigen, and forming a 
complex of peptides and MHCII molecule for presentation at the surface of the phagocyte (108).  
1.5.1 Humoral immunity to F. tularensis 





In T cell-rich areas of the lymphatics, primed APCs must come into contact with the naïve T cell 
(128).   Once antigen-specific T cells bind to the antigen displayed by MHCII, they are activated 
and travel back to the lymph nodes where clonal expansion of effector an memory T cells ensues 
(128).  It is important in vaccine development, to maximize  the number of recruited naïve T 
cells to encounter the antigen, thus improving the memory response (128).   After the initial 
infection, obsolete, primed or effector T cells apoptose, while other memory T cells continue to 
circulate in the body as sentinels (128).  A secondary memory response is initiated, after the 
same pathogen invades the host again.  This normally involves swift recognition of the antigen 
by CD4
+
 memory Th1 cells, which differentiate into Th1 cells that produce IFN-γ to help in the 
induction of CD8
+
 cytotoxic T cells (CTLs) to kill the infected cells (6, 93, 128).  CMI is 
primarily directed at microbes that survive in phagocytes and microbes that infect non-
phagocytic cells, whereas humoral immunity is directed to extracellular microbes.  
IFN-γ is an important cytokine in the protection against F. tularensis.  As shown by 
Anthony et al., when he exposed C57BL/6 mice exposed to F. tularensis after treatment with a 
monoclonal antibody to decrease the IFN-γ levels resulting in an increased susceptibility to 
tularemia, and at times a 15-fold increase in the amount of F. tularensis was recovered from the 
antibody-treated animals as compared to the controls (6).  In a study by Sjöstedt et al., it was 
shown that after stimulation with multiple F. tularensis protein antigens, CD4+ T cells, not CD8+ 
T cells, proliferated and produced IFN-γ.  However, if CD8
+
 T cells were stimulated with antigen 
for three days or if they were supplemented with IL-2, they would proliferate and produce IFN-γ, 
thus demonstrating the ability of CD8
+ 
T cells to produce IFN-γ, but only in response to initial 
CD4
+ 
T cell proliferation (145).  In a study by Chen et al., it was shown that the thymus, which 





initiated, suggesting a delayed primary immune response when compared to other pathogens 
(29).   
Some organisms predominantly elicit either humoral or cellular immune responses, but 
protection against most infectious diseases require a combination of the two, depending on 
various factors such as: inoculum size, route of infection, status of host immunity (35).  Since F. 
tularensis is an intracellular pathogen, it is commonly thought to rely solely on cell-mediated 
immunity (75, 159).  However, there have been multiple studies revealing the involvement of 
both arms of the adaptive immune response in combating F. tularensis.  When using 
subimmunogenic doses, F. tularensis LVS LPS has surprisingly been shown to elicit a specific, 
strong and long-lived anti-Francisella resistance, that appears to be dependent on IFN-γ and B-
cells (50, 165).  In a study by Sebastian et al., a combination of humoral and cellular response 
was invoked using components of F. tularensis (143). For the cell-mediated response, they 
immunized mice with F. tularensis LVS::wbtA, an O-polysaccharide (OPS)–negative mutant 
derived from the live vaccine strain of F. tularensis.  To induce the humoral antibody response to 
the OPS, which is a key virulence determinant for type A organisms, an OPS–tetanus toxoid  
(OPS-TT) glycoconjugate was used for immunization (143).  Mice received two doses of both 
vaccines, and after one month were challenged with  a lethal dose of F. tularensis LVS.  Mice 
that were given only one vaccine, either OPS-TT or the LVS::wbtA, succumbed to the infection 
within 5-7 days, whereas the mice receiving the combination vaccine didn’t show any signs of 
illness and survived.  Thus showing that a two-armed approach to the immune response can be 
more effective in vaccine development than a single-armed approach (143).  
 





F. tularensis is a Gram-negative bacterium, which mainly consists of an asymmetric 
outer membrane (OM), periplasmic space, cytoplasmic membrane, cytosolic region, Type IV pili 
(T4P), secretory systems and capsule (111) (Figure 1.2).  The lipid bi-layer of the OM is 
composed of an outer leaflet that is dominated by lipopolysaccharides (LPS) (Figure 1.2) (86, 
164).  The inner leaflet of the OM is composed of phospholipids and lipoproteins that link the 
 
Figure 1.2  Schematic drawing of the cellular envelope of F. tularensis.  The outer 
membrane consists of a asymmetric phospholipid and lipid A bilayer.  Lipopolysacharide 
makes up the outer membrane.  Capsule, exterior to the OM is not shown.  The 
peptidoglycan is interior to the OM and exterior to the cytoplasmic membrane which 
encases the cytosol.  The T4P complex is made up of PilQ in the OM and PilB, PilC, PilT 
and PilD in the CM.  PilA is cleaved by PilD and translocated through the inner membrane 
to form a pilin filament for secretion through PilQ protein to the surface of the bacterium. 
Figure adapted from Salomonsson et al (118) and White et al. (168).  
 





OM with the thin peptidoglycan located in the periplasm and encapsulate the cytoplasmic 
membrane (164), and additional proteins are associated with the outer membrane (88).  The 
capsule surrounds F. tularensis protecting it from serum-mediated lysis and is composed of the 
repeating polymer of the F. tularensis O-antigen subunit (7, 67).  Independent of capsule, long 
fibers of pili can be found interspersed at polar locations on the cells (67).  Components of each 
structure can contribute to the virulence of the bacterium as discussed in the following sections. 
LPS is a heat-stable, non-proteinaceous, non-secreted product present on the surface of 
Gram-negative bacteria and is usually involved in the stimulation of the immune system (164).  
The LPS of F. tularensis differs from other Gram-negative bacteria, in that it is a poor inducer of 
the immune response, does not have free phosphate moieties, exhibits low endotoxin activity, 
and thus is considered fairly non-toxic (5, 73, 136).  Even though it is a poor stimulator of the 
innate immune system, several studies have indicated that antibody-mediated protection 
developed to the LPS of F. tularensis LVS, can aid in the defense against tularemia (65, 107, 
159).  Mice immunized intraperitoneally (IP) with the lipopolysaccharides (LPS) of F. tularensis 
LVS were protected against an IP challenge of attenuated F. tularensis, however, they were not 
protected against the virulent SchuS4 strain (65, 165).   
The structure of F. tularensis LPS consists of lipid A, a short core oligosaccharide, and 
an O-antigen polysaccharide (OPS) side chain (164, 165).  The basic structure of lipid A is 
consistent among the F. tularensis subspecies with some substitutions between species (73).  The 
lipid A structure does not have phosphates on the 4-carbon of the non-reducing glucosamine 
residue and the adjacent reducing glucosamine lacks a free phosphate on the 1-carbon.  This  
may contribute to the low endotoxicity of F. tularensis lipid A as demonstrated by lipid A 





dephosphorylation in Salmonella, resulting in low endotoxic activity (165).  It is also possible 
that the cause of the weak endotoxicity of LPS in F. tularensis, as compared to highly endotoxic 
E. coli, is caused by the longer chain fatty acids of the F. tularensis lipid A, and the lack of 
acetylation on the three carbon of the non-reducing glucosamine (165).  
As in other Gram-negative bacteria, glucosamine-based, lipid A, aids in structural 
integrity of the membrane by acting as the hydrophobic anchor of LPS into the outer membrane 
portion of the bacteria (66, 130).  Unlike most Gram-negative bacterium, the lipid A portion of 
the F. tularensis LPS is not involved in activation of the innate immune system through 
recognition by human host cells expressing Toll-like receptor 4 (TLR4) pattern-recognition 
receptors (3).  The lack of phosphorylation on the non-reducing glucosamine of lipid A has been 
explored with respect to the biosynthetic process.  F. tularensis initially creates a 4′ phosphate, 
then uses the 4′ phosphatase LpxF, encoded by lpxF, to remove this group, thus enabling F. 
tularensis to avoid the host immune system (167).  Wang et al. created a mutant lacking lpxF, 
thus allowing a phosphate group to be left on the lipid A, resulting in the attenuation of the 
bacterium (167).  Therefore, the use of 4′ phosphatase LpxF mutant has been suggested as a 
potential vaccine candidate, since it can be recognized by the immune system and at the same 
time is attenuated (167). 
The core of LPS connects lipid A with the OPS and provides OM stability (92, 165).  The 
core does not contain any phosphate substituents and can be broken down into an outer region 
which is distal from lipid A, and the inner region which is directly linked to the lipid A via a 
single 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo) (92).  Unlike most Gram negative 
bacteria, where synthesis of LPS consists of two or three Kdo moieties, F. tularensis only attach 





mannose linked to Kdo instead of the heptose commonly found in other Gram-negative bacteria 
(165).  It appears that F. tularensis creates two Kdo units, but expresses Kdo hydrolase to 
eliminate the other unit.  Mutations in the genes that encode for Kdo hydrolase could affect the 
OM assembly and pathogenesis by decreasing the stability of the OM, leading to the attenuation 
of the bacterium and its possible use as a vaccine candidate (175).  
 The surface polysaccharide, O antigen (O Ag) linked to the core of LPS is composed of a 
repeating carbohydrate tetramer and is identical in F. tularensis ssp. tularensis and ssp. 
holarctica (31, 38, 142).  O Ag enables F. tulernsis to be resistant to serum-mediated lysis, as 
shown by the serum-susceptibility of a strain of F. tularensis with an O Ag mutation (31, 73).  
The O Ag mutation also resulted in decreased survival time of the bacterium within 
macrophages.  Deactivation of the wbtA-encoded dehydratase of the O Ag in F. tularensis LVS 
(LVS wbtA mutant) results in attenuation of the bacterium in the mouse model.  The attenuated 
strain has been used in vaccine testing with some conferred protection (142). 
The capsule protects F. tularensis from being killed via serum complement and can be 
thick or thin depending on if it is Type A or Type B F. tularensis, respectively (111).  The 
capsule of F. tularensis has been shown to increase the virulence of the bacterium and appears to 
be highly conserved among 14 type A and type B strains as shown by Apicella et al.(7).  CapB, 
CapC and CapA are part of a complex that is responsible for the biosynthesis of capsule (173).  
Removal of capB results in a >100-fold increase in attenuation of F. tularensis Schu4 in mice, 
thus indicating that the capBCA locus is essential for F. tularensis survival within the host.  
Further studies by Zhang et al. indicate the locus may facilitates escape from the phagosome and 
can halt phagosomal maturation, thus aiding in virulence (173).   





Hood et al. demonstrated the virulence of capsule by inoculating guinea-pigs with 
modified F. tularensis, in which the capsule removed, resulting in avirulence towards most 
guinea-pigs tested (86).  The capsular physiochemical analysis indicated that it is extremely 
similar to the composition of the LPS O-antigen with 50% lipid composition (7, 86).  Upon mass 
spectrometry (MS) analysis, Kdo and lipid A were not shown to be a component in the capsular 
antigen.  The studies done by Apicella et al. indicate that a purified capsule of O-antigen, free of 
LPS or other bacterial components, have the potential to protect against F. tularensis subsp. 
holarctica infection based on the active immunization by the capsule of F. tularensis, resulting in 
capsule-specific antibody production (7, 37). 
During invasion of the host by F. tularensis, outer membrane proteins or surface-bound 
proteins would potentially be the first structures encountered by the immune system (88).  Thus, 
identification and an understanding of these proteins would be important in vaccine development  
(88).  Some of the membrane proteins of F. tularensis were isolated in work done by Huntley et 
al., including previously identified FopA, Tul4 (88, 117, 147).  Using a 2DE immunoblot 
Huntley et al. identified 15 outer membrane proteins, with five as inducing antibody production 
during murine infection (KatG, PilQ, OmpA, FopA and Tul4-A) (88).  The identification of 
surface proteins can facilitate the further understanding of host-pathogen interactions.  
Another structure, called pilin, has been identified on the surface F. tularensis.  Pilin are 
long, thin structures located polarly in bundles, and have been noted to be involved in biofilm 
formation, host cell attachment, DNA uptake and twitching motility in other bacteria (67, 111).  
The long surface fibers characteristic of Type IV pili (T4P) are encoded by the pilA gene (67).  A 
protein complex of PilA, PilB, PilC, PilD, PilT, PilQ make up the T4P system in F. tularensis 





(118) (Figure 1.2).  PilQ is a pore-forming secretin located in the OM and facilitates secretion of 
PilA-derived multimeric pilus fiber (118).  In F. tularensis subspecies holarctica, T4P has been 
uncovered as an important factor in the virulence and spread of F. tularensis from initial site of 
infection (63).  In the study by Forslund et al, mice were infected with either a pilA deletion 
strain FSC354 or a pilin-expressing strain FSC352.  After 11 days the mice without the pilA 
gene, were able to clear infection from the spleen, whereas the mice infected with FSC352 
succumbed to the infection after 6 days (63). 
Adherence to mucosal membranes is also important for the molecular pathogenesis of 
infection (113).  It was shown by Melilli et al., that expression of FspA, an outer membrane 
protein of F tularensis, aids in its adherence to A549 human lung cells (113).  Of note, both F. 
tularensis LVS and the F. novicida express FspA, but F. novicida does not transport it to the 
outer membrane, so the ability of F. novicida to adhere to A549 lung tissue is greatly reduced 
when compared to F. tularensis LVS.  When mice were infected with F. tularensis, antibodies to 
the FspA protein were recovered (113).  Since FspA appears to aid in the virulence of F. 
tularensis and there is a recognizable immune response to it, it would be a likely vaccine 
candidate for a subunit vaccine. 
F. tularensis secretion systems were first described by Hagar et al., in which components 
of a Type IV pili homologue are indicated as a mechanism for protein secretion (74)  A protease, 
PepO, is secreted via the T4SS and plays a role in conversion of pre-endothelin into a robust 
vasoconstrictor to confine the bacterial infection to the skin (74).  The gene encoding this 
protease, pepO, is mutated in the Type A and Type B agents, thus allowing for better evasion of 
the immune system and increased virulence through evolution (74) 





The outer membrane (OM), which guards the bacterium from the environment, is 
asymmetric and can secrete OMVs (34).  The OMVs can encase immunogens and have been 
shown in previous studies to be potential vaccine candidates (34).  It is suggested that the 
Francisella pathogenicity island (FPI), made up of 33-kb gene cluster, encodes for the Type VI 
secretion system (T6SS) (20).  Membrane puncturing and core stabilizing proteins, VgrG and 
DotU respectively, are encoded by the FPI (20).  Without these two proteins, Francisella is 
unable to escape the phagosome, has decreased ability to multiply and thus has increased 
attenuation of the bacterium within the mouse (20).   
Mass spectrometers are used to further identify the protein through mass of the peptides 
derived by digestion of the protein, and their fragmentation profiles (49).  Once the peptides are 
separated and fragmented by tandem MS (MS/MS), computer programs  such as SEQUEST, 
Mascot, or X!Tandem are used to match spectra to previously identified protein sequences 
derived from genome sequencing data (114).  MS is not quantitative, due to the vast 
physicochemical properties exhibited by proteolytic peptides such as size, charge, 
hydrophobicity, etc.; therefore one cannot directly quantify each peptide, and differences in mass 
spectrometric response will result (12).  Comparison of individual peptides between experiments 
is required for accurate quantification (12).   
Label-free and stable isotope labeling are two of the platforms used to quantify proteins 
(174).  Stable isotope labeling (SIL) requires a specific mass tag to be incorporated into proteins 
or peptides metabolically, chemically, enzymatically, or through spiked synthetic peptide 
standards that can be recognized by a mass spectrometer (12).   The theory behind stable-isotope 
labeling is that peptides with or without labeling behave the same during MS analysis, therefore 





quantification can be achieved by comparing relative signal intensities of mass differences 
recognized by the mass spectrometer (12).  A few of the different types of stable isotope labeling 
are: Isotope-coded affinity tags (ICATs), stable isotope labeling by amino acids in cell culture 
(SILAC), isobaric tag for relative and absolute quantification (iTRAQ) (174, 177).  The benefit 
of SIL is its powerful, unbiased method for accurately determining changes in the levels of 
proteins and post-translational modifications (174, 177).  However, for quantification of levels of 
post-translational modifications the presence and signatures of modified and unmodified peptides 
would be information required prior to the analysis of SIL based data.  Some drawbacks to SIL 
are complex data analysis due to unequal incorporation of label into the peptide, and chemical 
cost for labeling higher sample concentration (12, 177).  Label-free methods compare two or 
more experiments via direct mass spectrometric signal intensity for a peptide or via calculations 
of frequency for protein-matching spectra as indicator for the relative abundance of the protein 
within a sample (12, 177).  The label-free strategy, has high reproducibility, requires less time 
and money due to omission of labeling reagents, and has no limit on the number of experiments 
that can be compared.  While this is a useful method for proteomic expression profiling of 
samples, where large numbers of changes between samples occur, this method can be biased in 
the quantification of individual proteins because it assumes  that each peptide in a protein has 
equal and  linear MS response (12, 174).   
Two of the more commonly used techniques of label-free quantification are spectral 
count-based LC-MS/MS and peak intensity-based comparative LC-MS (12, 174).  Relative 
quantification by peak intensity is generally calculated by direct comparison of multiple analysis 
of ion intensity changes as denoted by peak heights in chromatography (177).  The theory behind 





time.  As the peptide in the sample increases, so does the peak area, thus correlating linearly to 
the concentration of protein in the sample (177).  This type of quantification is geared towards 
clinical biomarker discovery, because of the high sample throughput required (177).  When 
compared to spectral count, the peak intensity method is more accurate in reporting changes in 
protein abundances, but requires complex computer programs (121).  The spectral count refers 
back to observation that the more a specific protein is seen in a sample, the more MS/MS spectra 
are collected for peptides of that protein (12). Therefore, relative abundance can be quantified by 
comparison of spectra between experiments (12, 177).  An advantage of quantification by 
spectral count over peak-intensity is that peptides common between datasets are not required for 
the protein ratio calculations, thus allowing for comparison of greater percentages of proteins and 
greater sensitivity (121).  
The work presented in this thesis investigated the immunogenicity of predicted F. 
tularensis LVS proteins.  The number of proteins predicted to be encoded on the F. tularensis 
LVS genome, which is based off the information from the Bioproject database located within the 
National Center for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/bioproject/16421), is 1754.  From these 1754 F. tularensis LVS 
proteins, we have narrowed our focus to nine proteins that were present and relatively abundant 
in fractions that elicited significant IFN-γ responses from splenocytes of F. tularensis infected 
mice.  The advantage of this research was the ability to narrow down the number of proteins for 
future studies as well as reinforce previously determined immunogenic proteins of F. tularensis 
LVS.   





The research was performed, based on the hypothesis that combining immunological 
assays for F. tularensis fractions containing multiple proteins, with MS/MS analysis of these 
same fractions, would lead to the identification of a defined set of antigens.  The question of 
whether or not a subunit vaccine is a viable preventative measure lies in the discovery of an 
immunodominant antigen of Francisella.  Can specific F. tularensis LVS protein fractions 
stimulate a memory T cell response and will it be strong enough to protect humans from virulent 
Type A tularemia?  Although the available F. tularensis LVS proteins were limited and there 
was some overlap during protein separation, mining the LVS proteome yielded positive results, 



















An aliquot of lyophilized F. tularensis strain LVS was received from The Center for 
Disease Control and Prevention (CDC, Fort Collins, CO).  Brain Heart Infusion (BHI) broth, 500 
µl, was added to rehydrate the F. tularensis LVS and mixed well.  Cysteine heart agar powder 
(Difco Cat. No. 0047-17-6) along with 9% sheep blood (Colorado Serum Co. 4950 York St. 
Denver, CO 80216) was used to create cysteine heart agar with chocolate sheep blood (CHAB) 
agar plates on which to grow F. tularensis.  CHAB agar was inoculated with 50 µl of the F. 
tularensis LVS suspension and incubated for 48 h at 37°C.  Single colonies were picked and 
inoculated to fresh CHAB plates and incubated for 48 h at 37°C until the colonies reached a size 
of about 2-4 mm.  With a sterile loop, colonies were collected to resuspend in cryovials 
containing 1 ml BHI broth and 10% glycerol.  The stocks were frozen at -80°C. 
Multiple growth media’s were evaluated to establish growth curves of F. tularensis and 
to visualize by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) protein 
contamination of the broth media.  After multiple trials using Chamberlain’s, Magar Traub, 
Mueller Hinton (MH) (Difco Cat. No. 275730) and Glycerol Alanine Salts (GAS) media, MH 
with an addition of 1% IsoVitaleX was chosen as the broth for batch growth of F. tularensis (25, 
81, 153).  The growth curve served as a good reference point for determining optical density 
(O.D.), which correlated with specific points on the growth curve, such as mid-log phase (Fig. 
3.2).  
CHAPTER 2 
MATERIALS AND METHODS 





A sterile wooden stick was used to transfer an inoculum of the F. tularensis LVS stock 
onto CHAB agar plates that were then incubated for 48 h at 37°C.  MH broth with IsoVitalex (75 
ml) was inoculated with a partial loopful of F. tularensis LVS colonies and incubated at 37°C 
with shaking at 150 RPM for 30 h until mid-log phase growth (~O.D. 1.0 A at 550 nm) was 
achieved.  The culture was aseptically subcultured at a 1:50 ratio into 1 L of MH with 
IsoVitaleX, and grown an additional 24 h in a shaking incubator at 37°C until mid-log phase 
(O.D. ~1.0 A at 550 nm).  Batch growth was repeated until about 28 L of culture were collected.  
An aliquot of each 1L culture was plated on LB agar and CHAB agar for quality control.   
The cells from the 28 L of culture were harvested using high speed centrifugation, at 
10,000 x g, 4°C, for 20 min (Sorvall SLC-6000 rotor) to separate culture supernatant (CS) from 
the bacterial cells.  The CS was decanted into a 4 L Winchester jug with 0.02% sodium azide to 
inhibit Gram-negative bacterial growth and stored at -20°C.  The pellet of F. tularensis LVS cells 
was suspended in about 12 ml phosphate buffered saline (PBS), pH 7.4, and centrifuged in 
Oakridge tubes at 10,000 x g, 4°C, for 20 min.  The supernatant containing PBS was carefully 
decanted.  The mass of the pellet was recorded and frozen at -80°C.  In total, 127.4 g of F. 
tularensis LVS cell pellet was collected from around 28 L of F. tularensis growth. 
Each Oakridge tube containing a frozen cell pellet of F. tularensis LVS was thawed on 
ice and suspended in 4 ml of breaking buffer, containing 1 EDTA-free protease inhibitor cocktail 
tablet (Roche Cat. No. 11873580-001) per 50 ml PBS, pH 7.4, 0.06 µg/ml DNase, 0.06 µg/ml 
RNase, and 1 µg/ml lysozyme.  An aliquot of the supernatant was carefully removed to analyze 
cell integrity by light microscopy.  The cell suspension was centrifuged at 10,000 x g, 4°C, for 
20 min.  The newly formed pellet was suspended in 4 ml breaking buffer, sonicated on ice, 60 





sec on and 60 sec off, with 3 repetitions.  In order to visually compare the degree of cell 
fragmentation pre- and post-sonication, samples were Gram-stained and viewed under a 
microscope.     
The cell lysate was centrifuged at 3,000 x g, for 20 min, to remove unbroken cells.  The 
supernatant was transferred to pre-weighed ultracentrifuge tubes, and centrifuged for 4 h, 4°C, at 
100,000 x g (SW28 rotor).  The supernatant containing cytosolic and periplasmic proteins 
(“soluble fraction”) was removed from the pellet containing membrane proteins (“membrane 
fraction”) and the membrane pellet was suspended in 10 ml breaking buffer, and transferred with 
a pipette into 50ml conical tubes.  The membrane and soluble fractions were frozen at -80°C (85, 
103).   
Soluble and membrane fractions were thawed on ice.  Dialysis tubing (3,500 MWCO) 
was prepared by boiling in dH2O for 7 min.  Soluble and membrane fractions were added 
separately to the prepared dialysis tubing, and dialyzed against 10 mM ammonium bicarbonate 
for 24 h, at 4°C, with three buffer changes.  After 24 h, the dialyzed material was collected into 
separate 50 ml conical tubes and aliquots of 100 µl were set aside for quality control.  The 
remaining material was frozen in 5 mg aliquots (5.g/l soluble and 14.4 g/l membrane) at -
80°C, and lyophilized.  The protein content of each fraction was measured using bicinchoninic 
acid (BCA) protein assay kit (Pierce Cat. No. 23255) as stated in manufacturer’s instructions 
(148).  SDS-PAGE and silver-staining were performed on each fraction (102). 
An aliquot (8 µl) of each sample protein fraction (5 µg) was mixed with 2 µl of 5X 
Laemmli loading buffer (63 mM Tris HCl, 10% glycerol, 2% SDS, 2.5% mercaptoethanol, 
0.0025% bromophenol blue, pH 6.8) (102).  The samples were boiled for 5 min, at 100°C, and 





centrifuged briefly in a microfuge (100).  Pre-stained markers (Bio-Rad Cat. No. 161-0374) and 
the denatured samples were loaded on a 10-20% Novex tris-glycine gel (Invitrogen Cat. No. 
EC61355BOX EC6135).  Electrophoresis was performed in 1X running buffer (25 mM Tris 
HCl, 192 mM Glycine, 0.1% SDS at pH 8.3) at 125 V.  Electrophoresis was terminated once the 
dye front reached the bottom edge of the gel.  Gels were then silver-stained for visualization of 
resolved proteins. 
Lyophilized protein fractions, from section 2.2, were dissolved with less than 1 ml of 
dH2O, and 5X Laemmli loading buffer (200 µl), to a concentration of 5 µg/µl.  Samples were 
boiled for 5 min, at 95°C, and centrifuged for 30 sec, at 10,000 x g.  Pre-made PROTEAN II 10-
20% tris-glycine gel was set up in PROTEAN II xi-Cell as directed by manufacturer (Bio-Rad 
Cat No. 165-1931).  Samples (5 mg) were loaded each gel and run initially for 30 min at 30 mA 
(800 V), immediately after which, the power was increased to 60 mA (800 V) for ~3 h until the 
dye-front reached the bottom of the gel.  Proteins were eluted from gel using the Whole Gel 
Eluter (Bio-Rad Cat. No. 165-1251) with 1X tris-CAPS buffer, 9.4 pH, operated at 250 mA for 
1.25 h.  Anode and cathode were reversed for 20 sec to loosen proteins from the membrane, and 
30 fractions (about 2.5 ml each) were eluted into harvesting chamber using a vacuum pump.  An 
aliquot (200 µl) of each fraction was dried in a Savant SpeedVac for about 3 h.  Samples were 
suspended with 40 µl Millipore dH2O.  An aliquot of each sample was run on a 1.0 mm x 15 well 
10-20% tris-Glycine gel (Invitrogen Cat. No. EC61355BOX) for 1.5 hr at 400 mA (200 V) 
thereafter, proteins were visualized by staining with silver nitrate.  Protein concentration of each 
sample was assessed using the BCA kit (Pierce Cat. No. 23225) (148). 





A total of five preparative SDS-PAGE runs were performed for the membrane and 
soluble protein preparations.  Final Whole Gel Eluter fractions were pooled accordingly based on 
protein size as observed with the silver-stained SDS-PAGE gels.  This resulted in a total of 16 
soluble protein fractions, and 19 membrane protein fractions.  The pooled fractions were 
lyophilized, sterilized with 24,000 Gy of γ-irradiation, and stored at -80°C.   
T cell assays were performed by Emily Kampf, in the laboratory of Catherine Bosio, 
using following protocol.  C57/BL6 mice were infected via intranasal inoculation with a 
sublethal dose (5,000 CFU) of F. tularensis LVS.  After 40 days, spleens, from five infected 
C57/BL6 mice and three uninfected mice, were harvested.  Spleens were placed in separate 15 
ml conical tubes (BD Cat. No. 352097), on ice, with ~3 ml Hank’s balanced salt solution (HBSS) 
(Gibco No. 14025).  Spleens were decanted into 70 µm nylon cell strainer (BD Cat. No. 52350) 
over an open tissue-culture dish (60 x 15 mm BD Cat. No. 353002).  Spleens were mechanically 
processed by forcing them through a strainer with the plunger end of a syringe (BD Cat. No. 
301603).  The strainer was rinsed 3 times using 5 ml HBSS.  All cells were transferred back into 
the original 15 ml conical tube, and ~8 ml fresh HBSS was added.  The spleens were centrifuged 
at 1,000 x g, for 5 min, at 4°C.  Supernatants were decanted to waste.  The cell pellets were 
suspended with 3 ml NH4Cl, and allowed to react for 3 min at room temperature (RT) to lyse red 
blood cells (RBC).  HBSS was added to each tube up to 10 ml, and the splenocytes collected by 
centrifugation at 1,000 x g, for 5 min, at 4°C.  The final cell pellet was suspended in 1 ml 
complete minimum essential medium (CMEM, Gibco Cat. No. 11095) per spleen.  All non-
infected controls were pooled into one 15 ml conical tube and all infected spleens were pooled 
into a separate 15 ml conical tube.  Splenocytes were counted under microscope with a 





hemocytometer counting chamber (Brightline Cat. No. 1492, Hausser Scientific) at a 1:30 
dilution of cells to live/dead trypan-blue stain for a total of 1 x10
8 
live cells / ml (infected mice) 
and 2.3 x 10
7 
live cells / ml (control mice).  Cells were diluted with CMEM to a concentration of 
2 x 10
6
 cells / ml and 100 µl aliquots of the splenocytes were placed in tissue-grade, 96-well, U-
bottom plates, with low evaporative lids (BD Cat. No. 353077).  The antigen fractions (10 µl at 
0.2 µg/µl) were added to appropriate wells.  A whole membrane antigen (final concentration of 
0.01 µg/µl), supplied by Dr. Bosio, was used as a previously proven, positive control (137, 145).  
Antigen was not added to negative control, standard or blank wells.  An additional 100 µl 
CMEM was added to each well for a final antigen concentration of 0.01 µg/µl.  The prepared, 
96-well plates were incubated at 37°C, with 5% CO2, for 3 days.  After 3 days, plates were 
removed from incubator and 150 µl of the supernatant was transferred, via pipette, into a fresh 
96-well plate.  The new plate was wrapped with parafilm and frozen at -80°C.   
Murine IFN-γ ELISA kit (R&D Cat. No. DY 485) was utilized to assay IFN-γ. The IFN-γ 
standard from the kit was diluted 1:30.  This primary standard was serially diluted at a 1:1 ratio 
until seven standards were created (1:30, 1:60, 1:120, 1:240, 1:480, 1:960, and 1:1920).  Reagent 
diluent was created to a final concentration of 0.1% bovine serum albumin (BSA Invitrogen) and 
0.05% tween20 in Tris buffered saline (20 mM Tris Base, 150 mM NaCl) at a pH of 7.3 and 
filtered through a 0.2 m filter. 
Capture antibody (50 µl / well) (rat anti-mouse IFN-γ diluted 1:180 in PBS from kit) was 
used to coat a 96-well ELISA plate (NUNC maxisorp Apogent Cat. No. 80040LE 0903) 
overnight at 20°C and the plate was washed using a plate washer.  The plate was blocked with 






washer.  Each standard (50 µl), and supernatants (50 µl) from antigen-stimulated splenocytes 
were added to the wells.  The plates were covered in parafilm, incubated at RT for 2 h, and 
washed with the plate washer.  Detection antibody (biotinylated goat anti-mouse IFN-γ diluted 
1:180 in reagent diluent, from kit) was added (50 µl) to each well, covered with parafilm and 
incubated for 1 h at RT, and the plate washed with the plate washer.  Streptavidin-HRP (50 µl of 
a 1:200 dilution) was added to each well.  The plate was covered in parafilm and incubated at RT 
in the dark for 20 min, and washed with the plate washer.  Color reagents A (H202) and B 
(tetramethylbezidine) were equilibrated to RT, and 50 µl (1:1 mixture of color reagent A and 
color reagent B) was added to each well, and incubated at RT, in the dark, for 20 min.  Stop 
solution (2N H2SO4) (50 µl) was added and mixed gently.  The plate was analyzed at 450 nm on 
a microplate reader and the data was plotted against a standard curve of IFN-γ.  The standard 
error was within 10% of the mean values. 
Preparative SDS-PAGE fractions (10 µg) were resolved on SDS-PAGE using 10-20% 
Novex tris-glycine gel (Invitrogen Cat. No. EC61355BOX EC6135) in 1X running buffer (25 
mM Tris HCl, 192 mM Glycine, 0.1% SDS at pH 8.3) at 125 V for 90 min.  The gels were 
stained with Coomassie Brilliant Blue R-250 (Bio-Rad) and the proteins of interest were excised 
with a razor blade.  Each excised gel section was cut into small pieces and placed in a de-
plasticized eppendorf tube.  De-plasticizing of tubes was done by filling with 60% acetonitrile 
and 0.1% trifluoroacetic acid (TFA), followed by mixing, incubation at RT for 1 hr and 
decanting.  The de-plasticizing step was repeated and tubes were dried with the Savant Speed-
Vac.  The gel pieces were de-stained with the de-stain solution (60% acetonitrile in 0.2 M 
ammonium bicarbonate, 0.1% TFA) at 37°C, for 30 min.  The solution was discarded and the de-





staining step was repeated until the stain was completely gone.  The gel pieces were dried in the 
Savant Speed-Vac.  To prepare the samples for MS/MS, each tube containing a gel piece was 
filled, until the gel was covered, with a modified trypsin solution (25 µg of trypsin in 300 µl of 
0.2 M ammonium bicarbonate).  The samples were incubated at RT until all the trypsin solution 
was absorbed, after which, 0.2 M ammonium bicarbonate was added in 10-15 µl increments until 
the gel was completely rehydrated and slightly covered in solution.  The samples were incubated 
overnight (O/N) at 37°C.  The reaction was stopped by adding 10% TFA (at 0.1 the digest 
volume).  The supernatant was collected and put in new de-plasticized tube.  Extraction solution 
(60% acetonitrile, 0.1% TFA) was added (100 µl) to each sample, the samples were mixed by 
vortexing and incubated at 37°C, for 40 min, with one vortex at 20 min.  The extract was 
centrifuged, the supernatant collected, and added to the previously collected supernatant.  This 
collection step was repeated.  The collected samples were dried in a Savant Speed-Vac until 1-2 
µl of liquid was left in the tube.  10 µl buffer A (5% acetonitrile, 0.1% acetic acid) was added to 
each sample and mixed, followed by centrifugation for 5 min.  Supernatant was transferred, via 
pipette, into autosampler vials and stored at -20°C until analysis by MS/MS (82, 134, 149).   
 Trypsin solution (10 µl) (25 µg trypsin and 300 µl 0.2 M ammonium bicarbonate) was 
added to dried antigen sample (10 µg), and allowed to digest overnight at 37°C.  After 24 h, 10% 
TFA (3 µl) was added to halt trypsin reaction.  The sample was dried in a Speed-Vac savant for 
10-15 min.  The sample was stored at -70°C until ready for MS/MS analysis.  Once ready for 
analysis, 10 µl of buffer A was added to the sample and mixed well.  Sample was centrifuged for 
5 min, at around 1,200 RPM and the supernatant (10 µl) was transferred to an autosampler vial.  
 





The peptides obtained via trypsin digestion, were resolved on a 0.2 × 50-mm C18 reversed 
phase HPLC column, (Agilent Technologies, Santa Clara, CA) using an Agilent 1100 capillary 
HPLC solvent delivery system at a flow rate of 5 μl/min with an increasing gradient of 
acetonitrile.  The eluent was guided directly into the linear trap quadrupole electrospray ion trap 
mass spectrometer (Thermo-Finnigan, San Jose, CA).  The operating conditions for the 
electrospray needle of the mass spectrometer were 4 kV, with a sheath gas flow of nitrogen at 30 
p.s.i., and a heated capillary temperature of 200°C.  Individual peptide ions were subjected to 
data-dependent MS/MS fragmentation.  Specifically, after a full MS scan the five most dominant 
ions were selected for fragmentation.  Dynamic exclusion was used to ensure multiple ions were 
analyzed, as each precursor ion was chosen a maximum of two times for MS/MS fragmentation 
and was placed on the dynamic exclusion list for 1 min.  MS/MS data were analyzed by 
SEQUEST software (Thermo Fisher Scientific, San Jose, CA; Version 27, Revision 12) against 
F. tularensis protein database (1754 entries) for protein identification (114).  The percent 
confidence of protein identification was determined by statistical analysis of the turbo SEQUEST 
search data using Scaffold (version Scaffold_3.3.1, Proteome Software Inc., Portland, OR) 
software.  Valid peptide and protein identifications were based on a two-peptide minimum per 
protein, a protein probability of 99.0%, and peptide threshold of 95%, as specified by the Peptide 











F. novicida and the live vaccine strain of F. tularensis holarctica, LVS, are often used as 
models for tularemia in biosafety level 2 laboratory research  This study involved the LVS strain 
as it’s model.  To define the best growth medium to evaluate protein antigens of F. tularensis, a 
number of different media were investigated as described in the material and methods.  It was 
found that MH, supplemented with 1% IsoVitaleX, was most consistent as a liquid growth media 
and did not appear to have interfering banding patterns when run on an SDS-PAGE gel (Fig. 
3.1A).  IsoVitaleX provides essential nutrients such as glucose, iron, cysteine, glutamine, 
adenine, thiamine pyrophosphate, guanine, and p-aminobenzoic acid (9). 
 
CHAPTER 3  
RESULTS 
3.1 Batch growth 
Figure 3.1 Silver-stained F. tularensis protein preparations resolved in 15% 
acrylamide gels by SDS-PAGE.  A) Lane 1; molecular mass marker (Bio-rad 
#161-0374).  Lane 2, Mueller-Hinton broth only.  B) Lane 1; molecular mass 
marker (Bio-rad #161-0374).  Lane 2, F. tularensis soluble fraction, Lane 3, F. 


























In order to ensure enough proteins were available for experimentation, 30 L of F. 
tularensis LVS were grown in MH broth supplemented with 1% IsoVitalex.  Rate of growth was 
quantified through measuring absorbance at 550 nm over a three to four day period.  Data from 
three separate runs were plotted and a polynomial trendline was graphed to illustrate the 
averaged growth curve (Fig 3.2). 
 
 
As for a solid medium, Francisella grows well on CHAB agar, as this provides the 
essential iron source for Francisella to grow.  F. tularensis is unable to grow on LB agar due to 
lack of cysteine (10, 68).  This knowledge was exploited to check for contamination, through 
simultaneously plating 1 ml of the 1 L batches of Francisella onto LB and CHAB plates.  All LB 
plates with any growth were traced back to the original 1 L batch growth and those contaminated 
batches were removed from further use in the experiment, leaving 27 L of viable F. tularensis.  

















MH 1%isovitalex OD 
Trendline 
Figure 3.2 Growth curve of F. tularensis LVS in MH with 1% IsoVitalex.  A two-
degree polynomial trendline is displayed in red to indicate the average of three 
separate growth curves for F. tularensis LVS.  The data was obtained using a 





novicida versus LVS, which prefers growth at 28°C versus 37°C, respectively (10, 56).  Thus, F. 
tularensis LVS was always grown at a constant 37°C.  The 1 L batches of F. tularensis were 
grown to mid-log phase, at which time the cells were harvested and the approximate 5 g of 
pelleted bacteria per liter were frozen at -80°C, until ready for use.  Of the 27 L of batch growth, 
a total of 128 g of F. tularensis LVS was obtained.   
The thawed cells were lysed through suspension in breaking buffer and probe sonication.  
The bacteria were determined to be sufficiently lysed through microscopic analysis of the Gram-
stained samples pre- and post-sonication.  The lysate was separated by centrifugation into crude 
membrane and soluble fractions.  To visualize the separation of these two fractions, they were 
analyzed by SDS-PAGE (Figure 3.1B).  The banding patterns representing the different 
molecular masses of proteins appeared to be slightly different between the two samples, 
suggesting there was at least partial uniqueness between the soluble and membrane fractions.  
Interference by the proteins from MH broth during growth of F. tularensis was deemed to not be 
a major contributor, due to its lack of banding patterns when analyzed by SDS-PAGE (Figure 
3.1A).  
The membrane and soluble proteins were separated by molecular weight via preparative 
SDS-PAGE, 5 mg at a time, and eluted via whole-gel elution.  After elution, the SDS-PAGE gels 
were stained with Coomassie Brilliant Blue R-250 (Bio-Rad) to ensure the electroelution was 
complete.  A total of 28 fractions were collected for each elution.  Each fraction was run on an 
SDS-PAGE gel and silver-stained to visualize the separation of proteins and for later use in 
determination of protein pooling (Fig. 3.3 and Fig 3.4). 
 









This process was repeated five times until the entire stock of membrane and soluble proteins 
were separated, eluted and visualized.  Since separation is not precise, there was overlap of 
Figure 3.4  Membrane proteins (lane 1-28) eluted after separation by SDS-PAGE.  
Lane M (marker) (Bio-rad #161-0374).  Each numbered lane contains proteins at a 
specific MW (~10 kDa to ~150 kDa) that were combined with complimentary 
proteins from each additional run (total of five gels processed).  The combination of 
the proteins can be seen in Figure 3.5.  15% acrylimide gel and silver stain.   
Figure 3.3 Soluble proteins (lane 1-28) eluted after separation by SDS-PAGE.  Lane 
M (marker) (Bio-rad #161-0374).  Each numbered lane contains proteins at a 
specific MW (~10 kDa to ~150 kDa) that were combined with complimentary 
proteins from each additional run (total of five gels processed).  The combination of 
the proteins can be seen in Figure 3.6. 15% acrylimide gel and silver stain.  



































neighboring proteins in every sample.  Also, due to some leakage during elution, final quantities 
varied between the five runs.  All lanes from the five gels for the membrane or soluble fraction 
were visually compared and the corresponding protein fractions with similar MW’s were pooled 
together into 19 membrane and 16 soluble fractions (Fig 3.5 and 3.6).  These protein samples 





Figure 3.6 Soluble proteins (lane 1-16) pooled from five whole gel elutions after 
SDS-PAGE.  Proteins range from ~10 kDa to ~150 kDA.  Measurement of 
proteins by lane M (marker) (Bio-rad #161-0374).  15% acrylimide gel and silver 
stain.   
Figure 3.5 Membrane proteins (lane 1-19) pooled from five whole gel elutions 
after SDS-PAGE.  Proteins range from ~10 kDa to ~150 kDA.  Measurement of 
proteins by lane M (marker) (Bio-rad #161-0374).  15% acrylimide gel and silver 



























The data presented and described in this section was provided from the laboratory of Dr. 
Catherine Bosio as a collaborative process.  C57/BL6 mice were intranasally-innoculated with 
live F. tularensis LVS and allowed to clear the infection over a 40 day period.  After 40 days, the 
spleens of five infected and three uninfected mice were removed and processed in order to 
cultivate the splenocytes.  Normal murine spleens can contain macrophages, dendritic cells, B-




T-cells, hematopoietic cells, plasma cells, plasmablasts 
and erythrocytes (24).  Complete composition of the splenocytes were not taken into account in 
the current study.  Non-infected murine splenocytes and infected murine splenocytes were 
compared for their reaction to each antigen.  The splenocytes were combined with the size-
fractionated membrane (19 samples) and soluble proteins (16 samples) and placed in 96-well 
plates in triplicate.  Whole F. tularensis membrane (0.01 µg/µl) was used as the positive control, 
while unstimulated splenocytes represented the negative control.  The wells were covered with 
CMEM and incubated for three days to allow for immune response to occur from processing and 
presentation of the antigen to the immune T cells.  After a three-day incubation period, IFN-γ 
secretion was quantified by an ELISA.  The amount of IFN-γ (pg/ml) produced by splenocytes of 
non-infected mice were subtracted from the IFN-γ (pg/ml) produced by splenocytes from 
infected mice tested against the same fraction (41).  The test was run in triplicate and error bars 
on the accompanying graphs (Fig 3.7 and Fig. 3.8) represent the standard deviation of each 
triplicate sample.  Seven fractions (membrane fractions 1, 2, 7 and soluble fractions 1, 3, 4, 5) 
were found to induce significant IFN-γ responses (p-value of <0.05) when compared to three-
fold greater than the average response of all membrane (314 pg/ml) or soluble (317 pg/ml) 





fractions (41).  The seven were chosen for further identification of protein composition by 






















IFN-γ minus naïve response  
Figure 3.7 IFN-production by T cells from LVS-infected and non-infected control 
murine splenocytes that were stimulated by 0.01 µg/µl pooled membrane proteins of 
F. tularensis.  Error bars reflect the standard deviation within the triplicate 
samples.  Average of all samples are indicated by a red line at 314 pg/ml. Stars 
indicate protein fractions that had a p-value of <0.05 that were further analyzed 
through MS/MS analysis. 






Figure 3.8 IFN-production by T cells from LVS-infected and non-infected control 
murine splenocytes stimulated by 0.01 µg/µl pooled soluble proteins of F. tularensis 
that were separated by MW.  Error bars reflect the standard deviation within the 
triplicate samples.  Average of all samples are indicated by a red line at 317 pg/ml  
Stars indicate protein fractions that have a p-value of <0.05 and were further 
analyzed through MS/MS analysis. 
 
Information gathered from the T cell assay via the ELISA readings indicated four soluble 
and three membrane fractions to have a three-fold higher than the average IFN-γ response (error 
taken into account) of the soluble (950 pg/ml) or membrane fractions (943 pg/ml) (see Fig. 3.7 
and Fig. 3.8).  This is in line with another F. tularensis immune assay in which T cells were 
stimulated with 0.01 µg/µl antigens to produce >400 pg/ml IFN- γ (125).  An aliquot (10 µg) of 
each of these seven fractions was resolved by SDS-PAGE.  The resulting Coomassie Brilliant 
Blue-stained bands were excised, digested with trypsin and analyzed via LC-MS/MS for 
identification of specific proteins.  This attempt to perform MS/MS analysis on in-gel digests 
provided poor results.  Another attempt at LC-MS/MS analysis was done using in-solution 



















IFN-γ minus naïve response 
3.4 MS/MS Analysis of Reactive Fractions 





determined that there was an overabundance of proteins per the 10 µg samples.  Specifically a 
total of 3 to 26 proteins were identified in each fraction.  Thus, for each fraction in solution, 
trypsin digestions were performed on 2.5 µg, 5 µg, and 10 µg of each fraction to compare the 
amount of proteins for differing concentrations.  This approach was designed to allow for 
analysis of an optimal protein amount and to help determine the most abundant proteins for each 
active fraction.  Additionally 5 µg of the non-INF- inducing fractions were analyzed by 
resolution trypsin digestion and LC-MS/MS (Table 3.1). 
The identification of proteins based on the LC-MS/MS data was accomplished using the 
SEQUEST software and statistical validation via the Scaffold software package (Proteome 
Software Incorporated, Portland, OR).  As assigned by the Protein Prophet algorithm, only 
proteins that had a 99% or greater confidence value and contained two or more unique peptides, 
were accepted (119).  Peptide identification was accepted when the probability based on the 
Peptide Prophet algorithm was >95% (97).  The parameters chosen in this study were set by Jeff 
Chandler during a similar study which defines the parameters for MS/MS analysis for the highest 
probability of correct peptide assignment and allows for ease of comparison between future 
research groups (97).   In general, 2.5 µg samples showed between one to 13 proteins per sample 
with an average of four proteins per sample.  The 5 µg samples allowed for identification of one 
to 14 proteins per sample with an average of eight proteins per sample, and the 10 µg samples 
allowed for the identification of three to 26 proteins in each sample with an average of 15 


















The LC-MS/MS performed on the 5 µg samples for seven T cell reactive fractions was 
used to define the putative T cell antigens.  This resulted in a list of 32 proteins (Table 3.1 and 
Appendix 1).  In order to determine whether the proteins were unique to active fractions, an LC-
MS/MS analysis was performed on trypsin digests (5 g) of the fractions that failed to stimulate 
strong T cell response.  The identification of proteins in these fractions (data not shown) showed 
that five of the 32 proteins were also present in the non-active fractions (Table 3.1).  Thus, the 
number of putative T cell antigens was narrowed to 27.  Of the 27 proteins, nine appeared to be 
relatively abundant.  However another protein, EF-Tu (FTL_1751), that was observed in non-
active fractions, was abundant based on the criteria described below and is a know antigen (79).  
Thus Ef-Tu was included in the list of dominant potential antigens.  The relative abundance of 
the proteins was defined as the ability to be detected not only in the 5 µg, but also in the 2.5 µg 
sample size (Table 3.2).  The 10 abundant proteins are listed in Table 3.1 and 3.2.  Of these, five 
were found in both the soluble and the membrane fractions at greater than 95% probability, 
13 
















C1 C3 C4 C5 M1 M2 M6 M7 
Proteins Identified Versus µg Sample Size 
using MS-MS  
2.5 µg 5 µg 10 µg 
no data 
available 
Figure 3.9 Number of proteins in each sample found after MS/MS analysis.  See 






indicating protein abundance in each fraction as a possible cause of the overlap (Table 3.2).  It is 
also possible that incomplete separation of membrane and soluble fractions caused the like-
proteins in both fractions as indicated by three of the 10 proteins not being found as abundant 
proteins.  In a similar murine study done by Dr. Jeff Chandler to identify the immunogenic 
surface proteome of F. tularensis, seven proteins matched those also found in the current study 
(Table 3.1) (27).  However, three of the seven proteins were not found in the membrane fraction 
of the current study, which could be due to the abundance of those proteins or incomplete 
fractionation.  Complete separation of the membrane fraction from the soluble fraction was not 
verified through enzymatic assays as done by other studies, but could be a good tool for future 






Table 3.1  Protein designation, name and percent confidence of identification of protein in 5 g sample, viewing only proteins 
with >95% peptide identification probability, as well as a >99% protein identification probability when containing at least two 
unique peptides. 












 confidence for 
identification of protein: 







FTL_1772 gi|89257037 *Aconitate hydratase 102688 0% 100% 0% 
FTL_0309 gi|89255740 Pyruvate dehydrogenase, E1 component 
c 
100254 0% 100% 0% 
FTL_0094 gi|89255534 *ClpB protein 
b 
96033 100% 91% 0% 
FTL_1504 gi|89256792 Peroxidase/catalase 
b,c 
81212 65% 100% 0% 
FTL_0234 gi|89255668 *Elongation factor G (EF-G) 77712 100% 99% 0% 
FTL_0267 gi|89255700 *Chaperone Hsp90, heat shock protein HtpG 72357 100% 91% 0% 
FTL_1191 gi|89256512 
*Chaperone protein dnaK (heat shock protein family 70 
protein) 
b,c
 69166 100% 100% 0% 
FTL_0768 gi|89256151 
GTP binding translational elongation factor Tu and G family 
protein  67619 0% 100% 0% 
FTL_1912 gi|89257160 30S ribosomal protein S1  61538 100% 100% 83%
m
 
FTL_0112 gi|89255549 Intracellular growth locus, subunit B 57902 100% 100% 0% 
FTL_1714 gi|89256983 *Chaperone protein, GroEL
 b,c
 57385 100% 100% 0% 
FTL_1797 gi|89257060 ATP synthase alpha chain 55520 100% 100% 0% 
FTL_1810 gi|89257073 N utilization substance protein A 55162 0% 100% 0% 
FTL_1783 gi|89257046 
*Dihydrolipoamide succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 
c
 52701 100% 93% 0% 
FTL_1478 gi|89256767 inosine-5-monophosphate dehydrogenase 52092 100% 0% 87%
s 
FTL_1479 gi|89256768 Cytosol aminopeptidase 51973 100% 0% 0% 
FTL_0572 gi|89255970 Hypothetical protein FTL_0572  51961 0% 100% 0% 
FTL_0311 gi|89255742 dihydrolipoamide dehydrogenase  50529 100% 0% 0% 





a) The percent confidence of protein identification as determined by statistical analyses of the SEQUEST search data using 
Peptide Prophet and Protein Prophet. 
b) Previously recognized as immunoreactive with human sera (79, 80, 104). 
c) Previously recognized as immunoreactive with mouse sera (27).   
*  Denotes abundant proteins as defined by not only being located in the 5 µg sample, but also in 2.5 µg sample. 
s) found in soluble fraction only. 
m) found in membrane fraction only.














 confidence for 
identification of protein: 







FTL_1591 gi|89256868 Acetyl-CoA carboxylase, biotin carboxylase subunit  50052 100% 0% 0% 
FTL_1795 gi|89257058 ATP synthase beta chain  49865 0% 100% 0% 
FTL_0891 gi|89256248 
*Trigger factor (TF) protein (peptidyl-prolyl cis/trans 
isomerase) 49554 100% 93% 0% 
FTL_0269 gi|89255702 *NAD(P)-specific glutamate dehydrogenase 49141 100% 100% 0% 
FTL_0283 gi|89255715 aromatic amino acid transporter of the HAAAP family  43518 0% 100% 0% 
FTL_1751 gi|89257020 *Elongation factor Tu (EF-Tu) 
b,c
 43372 100% 100% 100%
m
 
FTL_1553 gi|89256837 Succinyl-CoA synthetase beta chain  41542 100% 0% 0% 
FTL_1096 gi|89256426 Lipoprotein 41542 0% 100% 0% 
FTL_1328 gi|89256632 Outer membrane associated protein 
c





pyrophosphoryl-undecaprenol N-acetylglucosamine transferase  40698 100% 0% 0% 
FTL_1511 gi|89256798 glycerophosphoryl diester phosphodiesterase family protein  39077 0% 100% 0% 
FTL_1907 gi|89257155 Cell division protein 39727 0% 100% 0% 
FTL_0617 gi|89256014 hypothetical protein FTL_0617 
b







Table 3.2  Relative abundance of proteins and the fractions in which they were 
identified. Protein location extrapolated from Scaffold software (99% protein 
probability, 2 minimum peptides, and 95% minimum peptide probability) originating 
from 2.5 µg, 5 µg, 10 µg soluble and membrane fractions run on LC-MS/MS. 
 
Protein Totals MW
Locus Tag 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 kDa
FTL_1784 x 1 106
*FTL_1772  x x x x 4 103
FTL_0309 x x x x x 5 100
*FTL_0094 x x x x x 5 96
FTL_0588 x x x 3 82
FTL_1504 x x x x 4 81
*FTL_0234 x x x x x x 6 78
FTL_1537 x 1 76
*FTL_0267 x x x x x x x x 8 72
FTL_1407  x x 2 72
FTL_1464 x 1 71
*FTL_1191 x x x x x x x x x x x x 12 69
FTL_0768 x 1 68
FTL_0020 x x x x x 5 67
FTL_0438 x x  2 67
FTL_0828 x 1 67
FTL_1786 x x 2 66
FTL_0407 x 1 64
FTL_1947 x 1 63
FTL_1912 x x x x x x x x 8 62
FTL_0484 x 1 60
FTL_0112 x x x x x x x 7 58
FTL_1490 x 1 58
FTL_0310   x 1 57
*FTL_1714 x x x x x x x x x x x x 12 57
FTL_1797 x x x x x 5 56
FTL_0525 x 1 55
FTL_1810 x x 2 55
*FTL_1783 x x x x x x 6 53
FTL_1479 x 1 52
FTL_0572 x x x 3 52
FTL_1478 x x 2 52
FTL_0311 x x 2 51








Locus Tag 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 kDa
FTL_0453 x 1 50
*FTL_0891 x x x x 4 50
FTL_1334 x x 2 50
FTL_1527 x x 2 50
FTL_1591 x x x 3 50
FTL_1795 x x x 3 50
*FTL_0269 x x x x x x x x 8 49
FTL_1658 x 1 49
FTL_1908 x x 2 45
FTL_0283 x 1 44
*FTL_1751 x x x x x x x x x x x x x 13 43
FTL_1553 x x x 3 42
FTL_1410 x 1 41
FTL_1328 x x x x 4 41
FTL_1096 x x x x 4 40
FTL_1907 x x x x 4 40
FTL_1511 x x x 3 39
FTL_1146 x 1 35
FTL_0538 x 1 18
FTL_0617 x x 2 17
m2 m7s1 s3 s4 s5 m1
 
 
(s1, s3, s4, s5) soluble fractions.  
(m1, m2, m7) from membrane fractions. 
Items in red are also seen on Table 3.1.  
(Totals) the number of times each protein is identified regardless of location. 
(*) represent proteins of relative abundance as defined by the ability to be detected in not 






















At this time, there is not an approved vaccine for tularemia in humans (36, 91).  The 
previously-used vaccine, made from F. tularensis LVS, is no longer approved for human use due 
to the unclear source of attenuation and its variable immunogenicity (140).  The search for a safe 
and effective vaccine is ongoing and is the basis of this study.  Subunit vaccines employ 
specialized immunogenic proteins, that have the potential to illicit a better immune response, 
have fewer side-effects, and thus to be a more cost-effective than killed-vaccines (52).  Because 
these vaccines are only part of the whole organism, they do not run the risk of reverting to a 
pathological phenotype like the live-vaccines.  They can consist of, but are not limited to, one or 
more of the following components of the original bacteria: DNA, carbohydrate, or protein.  
Generally speaking, cellular immunity is used in protection against intracellular pathogens, and 
humoral immunity is best suited for protection against extracellular pathogens (99).  However, it 
has been suggested that, for a vaccine against tularemia to be most effective, both arms of the 
adaptive immune response, humoral as well as cellular immunity, must be evoked (99, 131, 143).  
The humoral response can be observed through antibody production via response of B cells.  
Cellular immunity is associated with T cell activation, via antigen presentation of peptides on the 
surface of APC cell.  The objective of the current study was to identify immunodominant 
antigens of F. tularensis, via measurement of the cellular immune response that could be used in 
a vaccine against tularemia. 
Previously published techniques for isolating immunodominant antigens of 
Mycobacterium tuberculosis were modified and used as a template for the current study (41).  A 
few of the limitations for using this method are incomplete resolution during SDS-PAGE, the 






possibility of poor membrane and soluble fraction separation and LC-MS/MS analysis by the 
Scaffold program.  We separated the intracellular pathogen, F. tularensis LVS, into membrane 
and soluble fractions, then into 28 membrane and 28 soluble protein fractions, based on 
resolution of molecular mass using preparative SDS-PAGE and whole gel elution (41).  The 28 
fractions were visually compared, and based on five SDS-PAGE gels, the fractions were 
combined into 19 membrane and 16 soluble fractions, to limit the samples for the T cell assay.  
 Mice (C57/B6) were inoculated with a sub-lethal dose of F. tularensis LVS by Emily 
Kampf and Dr. Bosio and the T cell-producing spleens were removed for use in the research 
presented here within.  The composition of the spleens was not assessed, nor were T cells 
isolated for this study.  While some antigen-containing fractions elicited a significant IFN-
response, had the spleens been depleted of interfering components, such as B cells, the 
resulting IFN- response may have been more robust.  Wolfe et al. showed that macrophages 
producing IL-10 decreased the amount of IFN- produced by IFN--producing splenocytes (171).  
In a study by Wijesuriya et al. it was found that B cells could interfere with the production of 
IFN- by T cells in tumor-bearing mice (170).  The method used in the current study, for 
evaluating cellular immune response in spleen populations, is a proven method (139) and if the 
IFN-response had been more robust, focusing the data to a manageable list may have been less 
successful.   
The previously-exposed splenocytes react with familiar protein antigens from each 
fraction to trigger the production and release of IFN-whereas the non-infected splenocyte 
(murine control) should not release IFN-Thus, in this study, the desired cellular immune 
response from the T cells, after incubation with the prepared soluble and membrane protein 





is one of the key indicators of the immune system recognizing a previously encountered foreign 
body.  Quantification of lymphocyte population and cytokine production in the spleen, via flow 
cytometry, could also be used to study the immune response (139).  However in this study, an 
ELISA test measuring the production of IFN-γ was used to quantify the immunological response.   
From the ELISA results, the chosen fractions of interest were statistically relevant (p-
value <0.05) to 3-fold that of the average IFN- (pg/ml) response for all 16 soluble or 19 
membrane fractions tested.  Each of the fractions were analyzed via LC-MS/MS to identify 
which proteins were in each fraction, and since each fraction contained multiple proteins, some 
of which may or may not stimulate an immune response, further analysis was required.  Each 
fraction was thus compared to itself at three different concentrations (2.5g, 5 g, 10 g) to 
identify the most abundant proteins in each fraction.  This step further narrowed the focus of 
possible immune-stimulating antigens from 1754 to 32.   
One way to test for relative abundance is through a technique called spectral counting.  
Spectral counting uses the number of times a peptide is identified by MS/MS in a single 
experiment, compares it to multiple experiments and transforms it into a measure for relative 
peptide abundance (97, 115).  Table 4.1 lists all 32 proteins in this study that were found in the 5 
µg IFN-producing fractions, with a short description.  Of the 32 proteins, only 10 proteins are 
detected in both 5 µg and 2.5 µg sample size, thus indicating their relative abundance as 
compared to the rest of the proteins.  These 10 proteins have been identified in Table 4.1 by an 
asterisk (FTL_1751, FTL_0269, FTL_0891, FTL_1783, FTL_1714, FTL_1191, FTL_0267, 







Table 4.1  Locus tag and description of the 32 unique vaccine candidates with the highest 
IFN-response as determined by LC- MS/MS with 5 µg sample.  
 
Locus Tag Description 
FTL_1772 *Aconitate hydratase- aconitase activity 
FTL_0309 Pyruvate dehydrogenase, E1 component- Thiamine pyrophosphate (TPP) family, 
E1 of E. coli PDC-like subfamily, TPP-binding module; composed of proteins 
similar to the E1 component of the Escherichia coli pyruvate dehydrogenase 
multienzyme complex (PDC) 
FTL_0094 *ClpB protein 
FTL_1504 Peroxidase/catalase  
FTL_0234 *Elongation factor G (EF-G)  
FTL_0267 *Chaperone Hsp90, heat shock protein HtpG 
FTL_1191 *Chaperone protein dnaK (heat shock protein family 70 protein) 
FTL_0768 GTP binding translational elongation factor Tu and G family protein 
FTL_1912 30S ribosomal protein S1- RPS1 is a component of the small ribosomal subunit 
thought to be involved in the recognition and binding of mRNA's during 
translation initiation. 
FTL_0112 Intracellular growth locus, subunit B  
FTL_1714 *Chaperone protein, GroEL-  GroEL_like type I chaperonin. Chaperonins are 
involved in productive folding of proteins. They share a common general 
morphology, a double toroid of 2 stacked rings, each composed of 7-9 subunits 
FTL_1797 ATP synthase alpha chain 
FTL_1810 N utilization substance protein A 
FTL_1783 *dihydrolipoamide succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex 
FTL_1478 Inosine-5-monophosphate dehydrogenase 
FTL_1479 Cytosol aminopeptidase 
FTL_0572 Hypothetical protein FTL_0572 
FTL_0311 dihydrolipoamide dehydrogenase 
FTL_1334 L-serine dehydratase 1 
FTL_1591 Acetyl-CoA carboxylase, biotin carboxylase subunit 
FTL_1795 ATP synthase beta chain 
FTL_0891 *Trigger factor (TF) protein (peptidyl-prolyl cis/trans isomerase)- molecular 
chaperone 
FTL_0269 *NAD(P)-specific glutamate dehydrogenase  
FTL_0283 aromatic amino acid HAAP transporter - amino acid permease 
FTL_1751   *Elongation factor Tu (EF-Tu) (b)-EF-Tu subfamily.  “This subfamily includes 
orthologs of translation elongation factor EF-Tu in bacteria, mitochondria, and 
chloroplasts.  It is one of several GTP-binding translation factors found in the 
larger family of GTP-binding elongation factors” 
FTL_1553 Succinyl-CoA synthetase subunit beta (sucC)- “catalyzes the interconversion of 
succinyl-CoA and succinate”  
FTL_1096 Lipoprotein- “DsbA family, Com1-like subfamily; composed of proteins similar 





FTL_1328 Outer membrane associated protein- OmpA family (fopA).  “The Pfam entry 
also includes MotB and related proteins which are not included in the Prosite 
family”  
FTL_1410 undecaprenyldiphospho-muramoylpentapeptide beta-N- acetylglucosaminyl-
transferase- “involved in cell wall formation; inner membrane-associated; last 
step of peptidoglycan synthesis” 
FTL_1511 glycerophosphoryl diester phosphodiesterase family protein 
FTL_1907 Cell division protein- “FtsZ is a GTPase that is similar to the eukaryotic tubulins 
and is essential for cell division in prokaryotes.  FtsZ is capable of polymerizing 
in a GTP-driven process into structures similar to those formed by tubulin.” 
FTL_0617  hypothetical protein FTL_0617-  “Bacterioferritin (cytochrome b1) [Inorganic 
ion transport and metabolism]” 
 
Extrapolated from http://www.ncbi.nlm.nih.gov/protein 
* denotes relatively abundant proteins. 
 
In a study for the identification of immunogenic F. tularensis surface proteins by Dr. Jeff 
Chandler, four of these ten relatively abundant proteins were identified to be immunoreactive 
with mouse sera, as noted on Table 3.1 (FTL_1191, FTL_1714, FTL_1783, FTL_1751) (27).  Of 
these four proteins, only one in the current study was found in only the soluble fraction at >95% 
probability, whereas three proteins were found in both soluble and membrane fractions 
(FTL_1191, FTL_1714, FTL_1751), leading to concerns of separation and actual location of the 
protein in current study (Table 3.1).  
The separation of membrane from soluble fractions was accomplished via centrifugation 
after lysis of bacterial cells, subsequently each fraction was further separated by MW via SDS-
PAGE.  These two techniques allowed for possible incomplete separation on both the membrane-
soluble interface and between the MW fractionations.  This may account for some overlap in the 
immunogenic proteins of these subcellular fractions, as well as adjacent MW fractions.  
Theoretically, if proteins overlap from one group to another, there should also be overlapping 
IFN-γ responses between groups.  Multiple proteins were also observed in each immune fraction.  





For example, in Table 3.2, NAD(P)-specific glutamate dehydrogenase (FTL_0269) is found in 
five of the seven active fractions (soluble 3, soluble 4, soluble 5, membrane 2, and membrane 7).  
This could suggest either FTL_0269 is the immunogen of all five fractions.  Alternatively, the 
presence of this protein could be coincidental and reactivity is due to some other protein in each 
fraction. 
EF-Tu is another protein identified within the study, and is typically found to be in the 
cytoplasm, however, Barel et al. only reported finding it the membrane region of F. tularensis 
(13, 88).  In the current study, EF-Tu (FTL_1751) was found in both membrane and soluble 
fraction, thus, the data from Barel et al. reinforces the idea of incomplete separation of the 
proteins within this study (13).  Since this protein was also found in both the IFN--inducing and 
the non-IFN--inducing fraction, the question arises as to why it has previously been shown to 
illicit and immune response, but has conflicting results in the current study (13).  It is possible 
there are products within the non- IFN--inducing fractions, that inhibited the in vitro T cell 
assay; or there is not enough antigen in the non-inducing fraction to react with the primed T 
cells.  Whereas, the proteins were analyzed by the Scaffold program at 95% peptide probability 
and 99% protein probability with 2 unique peptides, this was chosen to set a standard between 
studies within the Belisle lab and could be altered.  If in fact this is changed in any way, there is 
a chance that other proteins will appear more dominant in each fraction and the results could 
change slightly.  In a study of it’s function, Barel et al. found that protein EF-Tu played an 
important role in F. tularensis infectivity as an LPS ligand facilitating the adhesion and entry of 
F. tularensis into human monocytes via surface nucleolin receptor (13).  Thus, EF-Tu would 
make a good candidate for therapeutic interference of F. tularensis infections in hopes of 





involvement in the virulence of F. tularensis, the argument is strengthened for the 
immunogenicity of the EF-Tu protein antigen within the current study, regardless of their 
location in the non-inducing fractions.   
Chaperone, heat shock, or surface proteins would be good immunogenic protein 
candidates, because they are necessary to obtain entry into the cell or for survival of the 
bacterium within the cell (27, 58, 59).  The intracellular compartment where F. tularensis resides 
is very hostile, and the upregulation of stress genes is necessary for continued life and 
proliferation (59, 105).  Through 2-D PAGE, Lenco et al. identified proteins that were 
upregulated within the macrophage in response to oxidative pressure (105).  Some of the proteins 
found in the Lenco et al. study overlap with proteins found during the current study (Hsp90 
(FTL_0267), GroEL (FTL_1714), DnaK (FTL_1191), ClpB (FTL_0094)), reinforcing these as 
possible vaccine candidates (105).  Other proteins from the current study may be beneficial 
candidates for vaccine developement, due to their requirement for entry or survival of the 
bacterium within the cell (EF-G (FTL_0234), TF (FTL_0891), NAD(P)-specific glutamate 
dehydrogenase (FTL_0269), dihydrolipoamide succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex (FTL_1783), and aconitate hydratase (FTL_1772)).  While these 
proteins were not found in the study by Lenco et al., the majority of these proteins have been 
confirmed by previous studies as immunogenic for F.tularensis and identified in the current 
study (8, 11, 13, 69, 106, 112, 172, 176, 178). 
There is additional evidence that proteins involved in the virulence of F. tularensis are 
likely vaccine candidates or immunogens.  For example, in E. coli, Zolkiewski et al. 
demonstrated cooperation of DnaK and ClpB within the macrophage, to disaggregate and 





Later, Meibom et al. demonstrated ClpB protein of F. tularensis to contribute to intracellular 
multiplication as well as to be essential for replication and disease proliferation in target organs 
(112).  Bakshi et al. showed DnaK, and GroEL upregulation during oxidative stress, by 
intranasal inoculation of mice with F. tularensis LVS or sodBFt, followed by intranasal challenge 
with Schu4 after 14 days (11).  This upregulation was more abundant in the sodBFt mutant, an 
attenuated form, than wild type F. tularensis LVS, thus indicating it’s possible use as an 
attenuated vaccine strain (11).   
The protein dihydrolipoamide succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex (FTL_1783), found in the soluble and membrane fraction of 
F.tularensis during the current study, has also been identified as an immunoreactive protein in 
intracellular pathogen Bartonella henselae, the causative agent of cat-scratch fever (69).  
Gilmore et al. detected the protein with antiserum from experimentally infected mice (69).  In a 
study by Litwin et al., this protein was also shown to be cross-reactive in F. tularensis among 
other intracellular pathogens (106).  This leads to positive reassurance that the FTL_1783 
protein, found in this study, could be a realistic protein to use for future vaccine studies against 
F. tularensis. 
  Whereas outer membrane protein, FopA, was not found in the current study as an 
immunogenic antigen, Hickey et al. have incorporated it into a recombinant subunit vaccine.  
They showed that a single outer membrane protein (FopA) within a subunit vaccine was enough 
to provide protection and clearance of F. tularensis LVS (84).  The FopA protein however, was 
not enough to provide complete protection against the F. tularensis Schu4 strain, but speculated 
the use of multiple proteins could increase the protective ability of their vaccine (84).  They were 





also demonstrating humoral immunity playing a role in protection (84).  Procedures extrapolated 
from Hickey et al. could be used in conjunction with the protein data that has been identified 
within the current study to move forward in creation of a subunit vaccine. 
Another way to vaccinate against tularemia could be through the use of a DNA vaccine.  
While the subunit vaccine has an expected MHCII antigen presentation, due to exogenous 
protein uptake by APCs, DNA vaccines would mostly display antigens through MHCI 
presentation, due to the proteins being translated from within the APCs.  Also, since F. tularensis 
gets taken up into the APC’s and escape to the cytosol for replication, a DNA vaccine may 
mimic a response closer to the real infection than a non-replicating subunit vaccine.  A vaccine 
study done by Yang et al. in 2005, on intracellular pathogen, Brucella melitensis gives insight 
into the possibility of DNA vaccines as a quick way to screen for potential antigens (172).  Yang 
et al. states that the DNA vaccine is more cost-effective, easier to develop and induces long-
lasting immunity as compared to the traditional protein subunit vaccine (172).  They were able to 
identify two genes, the chaperone protein, trigger factor (TF) and the periplasmic protein, bp26 
(172).  When the genes were introduced as DNA vaccines, they caused a reduction in splenic 
colonization by >0.6 log over the control, which was an arbitrary number Yang et al. set to 
distinguish satisfactory protection (172).  When used together as a vaccine they induced a mix of 
humoral and cellular immune response (172).  TF is a potential vaccine candidate for 
intracellular pathogen F. tularensis, as shown by it’s ability to induce IFN- in both the soluble 
and membrane fractions of this study.  Even though it does not show any sequence homology to 
the Brucella melentisis, this does show proof of principle for testing the F. tularensis antigens 





A future assay to determine good candidates could include prediction of novel T cell 
epitopes to facilitate vaccine design, as described by Kim et al. (98).  The general idea behind the 
use of T-cell epitopes in vaccine design, is for a vaccine to induce memory T cell population 
capable of recognizing the pathogen (98).  While the possible vaccine has to contain antigens 
that harbor T cell epitopes from the specific pathogen, it does not have to be made of individual 
epitopes (98).  These epitopes can be screened by using the tools found on the immune epitope 
database (IEDB- http://www.immuneepitope.org/).  Once the antigens are identified, they can be 
checked for expression by the pathogen and for immunogenicity during infection.  This can be 
done by challenging human T cells obtained after an infection.  These chosen antigens then can 
be tested for conservation within the species.  If these antigens appear to stimulate the immune 
response, a large scale manufacturing of these antigens for clinical trials could be a next step.  
Animal immunization could be performed to test for a protective response and then on to human 
trials.  However, since this pathogen is so infectious, we will need to find a better way to check 
humans for immunity.  A study by Pascalis et al., compared an in vivo murine assay with the in 
vitro functional activity of immune lymphocytes derived from vaccinated mice, and relative gene 
expression in immune lymphocytes to find the correlates of protection against F. tularensis (45).  
They define correlates as “a measurement that detects relevant biological functions critical for, 
and statistically related to, protection against an infectious disease” (45).  By extrapolating the 
experiments from their study into the current study, it would be possible to get a better grasp on 
the specific antigens that would be best suited for a possible future human study. 
At a minimum, the data here represents a starting point for further protein analysis by 
limiting the possible antigens to a manageable number, bringing us one step closer to finding an 
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Protein accession number: gi|89257037 Number of total spectra: 2 
Protein name: aconitate hydratase [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220604 - S1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 102688.3 Amino Acid Coverage:  2.56% 





























98.20% PFVKTSLAPGSQVVTQYL K E 80.50% 1.59 0.251 0 1935.06 467 484 
98.20% VILAGK L E 75.50% 1.12 0.157 0 600.41 769 774 
 
Protein accession number: gi|89255700 Number of total spectra: 11 
Protein name: Chaperone Hsp90, heat shock protein HtpG [Francisella tularensis subsp. holarctica] Number of unique spectra: 9 
Fraction MS/MS sample name: 8220604 - S1 (5g) Number of unique peptides: 6 
Protein molecular weight (Da): 72357.1 Amino Acid Coverage: 10.5% 



























100.00% AAANNPQLEAFK K K 95.00% 1.22 0.471 5.19 1273.65 441 452 
100.00% FLESLTGDK K S 95.00% 1.69 0.376 1.92 1009.52 104 112 
100.00% FWDSFGQVLK K E 89.40% 0.775 0.0043 2.38 1226.62 375 384 
100.00% GDIDLDKFETPENK K E 95.00% 2.03 0.355 10.3 1620.78 487 500 
100.00% KYTFETEVDK K L 95.00% 1.22 0.183 3.89 1259.62 5 14 





Protein accession number: gi|89257160 Number of total spectra: 2 
Protein name: 30S ribosomal protein S1 [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220604 – S1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 61653 Amino Acid Coverage: 3.42% 


























98.00% QLSEDPFK K N 91.80% 0.945 0.0941 2.51 963.48 434 441 





Protein accession number: gi|89256512 Number of total spectra: 41 
Protein name: Chaperone protein dnaK (heat shock protein family 70 protein) [Francisella tularensis subsp. holarctica] Number of unique spectra: 24 
Fraction MS/MS sample name: 8220604 - S1 (5g) Number of unique peptides: 11 
Protein molecular weight (Da): 69165.5 Amino Acid Coverage:  17.1% 




























100.00% ALEEAFAPIAQK K A 95.00% 1.26 0.475 4.44 1287.69 592 603 
100.00% EEAFAPIAQK L A 95.00% 1.19 0.438 0 1103.57 594 603 
100.00% FDLADIPPAPR R G 70.70% 0 0 1.82 1211.64 459 469 
100.00% FESLVSDLVMR K S 95.00% 1.64 0.32 4.16 1295.67 307 317 
100.00% FHDLVTAR K N 95.00% 1.21 0.374 1.04 958.51 531 538 
100.00% GILNVSAK N D 87.00% 1.27 0.3 0 801.48 484 491 
100.00% 
KEEDVVDADFEDV
EDDKK K - 95.00% 2.82 0.671 8.66 2124.95 625 642 
100.00% MAPPQVSAEVLR K K 95.00% 1.44 0.524 6.8 1313.69 112 123 
100.00% NTADNLIHSSR R K 95.00% 0 0 3.37 1227.61 539 549 
100.00% SSSGLSEEDIEK K M 95.00% 0.935 0 2.89 1280.59 505 516 
100.00% YLIDEFK N K 95.00% 1.6 0.403 0 927.48 241 247 
 
Protein accession number: gi|89255534 Number of total spectra: 6 
Protein name: ClpB protein [Francisella tularensis subsp. holarctica] Number of unique spectra: 4 
Fraction MS/MS sample name: 8220604 - S1 (5g) Number of unique peptides: 4 
Protein molecular weight (Da): 96032.7 Amino Acid Coverage: 5.24% 



























100.00% GLEELWK K A 85.40% 1.54 0.232 0 874.47 457 463 
100.00% LADAGFDPVFGAR K P 95.00% 1.17 0.386 0 1335.67 804 816 
100.00% NNPVLIGEPGVGK K T 95.00% 1.49 0.214 4.07 1293.72 200 212 













Protein accession number: gi|89257046 Number of total spectra: 2 
Protein name: dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex [Francisella 
tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220604 - S1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 52700.5 Amino Acid Coverage:  4.09% 



























99.50% GLVVPVLR R D 89.00% 1.32 0.247 1.68 852.57 362 369 
99.50% SLAELEADVLDK K A 95.00% 1.62 0.393 4.64 1302.68 375 386 
 
Protein accession number: gi|89255668 Number of total spectra: 3 
Protein name: elongation factor G (EF-G) [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220604 - S1 (5g) Number of unique peptides: 3 
Protein molecular weight (Da): 77712.4 Amino Acid Coverage:  3.84% 



























100.00% ANVVPVQL K N 93.30% 1.07 0.339 0 839.5 164 171 
100.00% FVDEVVGGVVPK K E 95.00% 1.29 0.494 8.22 1244.69 536 547 
100.00% GVIDLIR K M 95.00% 1.52 0.0619 5.85 785.49 181 187 
 
Protein accession number: gi|89257160 Number of total spectra: 2 
Protein name: 30S ribosomal protein S1 [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 61653 Amino Acid Coverage:  4.5% 



























99.80% SESFIPVSSLK K N 95.00% 1.08 0.38 1.68 1193.64 44 54 






Protein accession number: gi|89257060 Number of total spectra: 3 





Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 55520.1 Amino Acid Coverage:  4.87% 




























99.80% ILEVPVGEALLGR R V 95.00% 1.61 0.447 4.17 1365.81 94 106 
99.80% VVDALGNPIDGK R G 95.00% 0.987 0.333 6.6 1197.65 107 118 
 
Protein accession number: gi|89255700 Number of total spectra: 2 
Protein name: Chaperone Hsp90, heat shock protein HtpG [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 72357.1 Amino Acid Coverage:  6.05% 





































99.90% FWDSFGQVLK K E 95.00% 0.955 0.309 3 1226.62 375 384 
99.90% 
QTVSLADYISRMKESQDTIYYITSDS
YK K A 95.00% 1.39 0.353 0 3305.59 413 440 
 
Protein accession number: gi|89256512 Number of total spectra: 6 
Protein name: Chaperone protein dnaK (heat shock protein family 70 protein) [Francisella tularensis subsp. holarctica] Number of unique spectra: 5 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 3 
Protein molecular weight (Da): 69165.5 Amino Acid Coverage:  6.39% 





























100.00% ALEEAFAPIAQK K A 95.00% 0.976 0.405 3.89 1287.69 592 603 
100.00% FDLADIPPAPR R G 95.00% 0.849 0.0946 5.72 1211.64 459 469 












Protein name: Chaperone protein, groEL [Francisella tularensis subsp. holarctica] Number of unique spectra: 25 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 15 
Protein molecular weight (Da): 57385.4 Amino Acid Coverage:  36.2% 
































100.00% AAVEEGIVAGGGVALIR R A 95.00% 2 0.484 4.92 1581.9 405 421 
100.00% ALDGLTGENDDQNHGIALLR K K 95.00% 0 0 6.46 2122.05 425 444 
100.00% AVTAGMNPMDLK K R 95.00% 0 0 3.51 1263.61 106 117 
100.00% DLLPILEGVSK R S 84.90% 0 0 2.04 1183.69 232 242 
100.00% DTYGDMVEMGILDPTK N V 87.60% 1.44 0.278 0 1816.8 483 498 
100.00% GFEDELDVVEGMQFDR K G 93.30% 0.945 0.189 3.24 1885.83 182 197 
100.00% LEETNMEHLGTASR K V 95.00% 0 0 4.34 1603.74 309 322 
100.00% LSGGVAVIK K V 95.00% 1.73 0.312 2.59 843.53 372 380 
100.00% LTEGLK L A 92.50% 1.44 0.21 0 660.39 100 105 
100.00% MITTEAMIGEIK L E 95.00% 2.19 0.421 0 1352.68 514 525 
100.00% PILEGVSK L S 83.10% 1.11 0.198 0 842.5 235 242 
100.00% QIVSNAGGESSVVVNQVK R A 95.00% 1.39 0.438 6.75 1814.96 453 470 
100.00% QVLFSDEAR K A 77.30% 1.09 0.313 0 1064.54 5 13 
100.00% SIEQVGTISANSDATVGK K L 95.00% 1.73 0.59 0.495 1776.9 143 160 
100.00% 
TADVAGDGTTTATVLAQALL
TEGLK K A 86.10% 0 0 2.08 2417.28 81 105 
 
 
Protein accession number: gi|89256768 Number of total spectra: 2 
Protein name: cytosol aminopeptidase [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 51973 Amino Acid Coverage:  7.72% 


































99.80% GGNEGDAPIVLVGK K G 95.00% 1.65 0.372 3.59 1325.71 237 250 
99.80% 
QAAGMDSMKMDMGGVAAVMG




Protein accession number: gi|89257020 Number of total spectra: 18 





Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 9 






























100.00% GEAGDNVGILVR R G 95.00% 1.35 0.36 8.36 1199.64 269 280 
100.00% GITINTSHVEYESPNR R H 95.00% 2 0.371 2.39 1816.88 60 75 
100.00% GVVNVGDEVEVVGIRPTQK R T 95.00% 1.46 0.316 1.85 1995.09 235 253 
100.00% HTPFFK R G 88.80% 1.5 0.22 0.699 776.41 320 325 
100.00% IVELVQAMDDYIPAPER K D 95.00% 0.984 0.101 3.66 1958.99 189 205 
100.00% IVVFLNK K C 77.00% 1.25 0.0857 1.92 832.53 131 137 
100.00% MTITLINPIAMDEGLR K F 95.00% 1.09 0.358 2.28 1787.94 359 374 
100.00% PQFYFR R T 95.00% 1.52 0.401 0 857.43 329 334 
100.00% TTVTGVEMFR K K 95.00% 1.04 0.268 3.68 1140.57 254 263 
 
Protein accession number: gi|89255549 Number of total spectra: 7 
Protein name: intracellular growth locus, subunit B [Francisella tularensis subsp. holarctica] Number of unique spectra: 6 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 4 
Protein molecular weight (Da): 57901.5 Amino Acid Coverage: 7.71% 

























100.00% ALEQEWLK R V 95.00% 0.941 0.125 2.72 1016.54 99 106 
100.00% KEELQYDFER K N 95.00% 0 0 2.82 1356.64 127 136 
100.00% NIDFDVSDDASK K V 95.00% 0 0 3.3 1325.59 28 39 
100.00% SIISNDEFR N A 84.80% 1.15 0.321 0 1080.53 90 98 
 
Protein accession number: gi|89255702 Number of total spectra: 3 
Protein name: NAD(P)-specific glutamate dehydrogenase [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220609 – S3 (5g) Number of unique peptides: 3 
Protein molecular weight (Da): 49141 Amino Acid Coverage: 8.91% 



























100.00% EVFSTLKPALEHNPK K Y 94.60% 0 0 2.55 1709.92 30 44 
100.00% GFVHDPEGITTDEK K I 95.00% 1.71 0.428 6.24 1544.72 267 280 
100.00% LSWSAEEVESK R L 95.00% 1.03 0.293 2.85 1264.61 392 402 
           Protein accession number: gi|89256248 Number of total spectra: 2 





Fraction MS/MS sample name: 8220609 - S3 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 49553.8 Amino Acid Coverage: 4.8% 
           Protein 
identification 





















98.80% IEVQKPVVELTDK K E 95.00% 1.97 0.315 4.82 1497.85 122 134 
98.80% VTIDFVGK K K 75.40% 0.777 0.198 1.77 878.5 163 170 
 
Protein accession number: gi|89255702 Number of total spectra: 5 
Protein name: NAD(P)-specific glutamate dehydrogenase [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220612 – S4 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 49141 Amino Acid Coverage: 6.01% 



























99.80% FLGFEQVFK K N 95.00% 1.25 0.375 3.52 1114.59 108 116 
99.80% HIGPDIDVPAGDIGVGGK R E 95.00% 1.67 0.394 3.01 1716.89 157 174 
 
Protein accession number: gi|89257020 Number of total spectra: 9 
Protein name: elongation factor Tu (EF-Tu) [Francisella tularensis subsp. holarctica] Number of unique spectra: 8 
Fraction MS/MS sample name: 8220615 – S5 (5g) Number of unique peptides: 4 
Protein molecular weight (Da): 43372.2 Amino Acid Coverage:  11.2% 

























100.00% GEAGDNVGILVR R G 95.00% 1.42 0.265 7.1 1199.64 269 280 
100.00% INPIAMDEGLR L F 95.00% 1.51 0.305 0 1244.63 364 374 
100.00% TTVTGVEMFR K K 95.00% 1.05 0.332 2.52 1140.57 254 263 












































Protein accession number: gi|89256512 Number of total spectra:11 
Protein name: Chaperone protein dnaK (heat shock protein family 70 protein) [Francisella tularensis subsp. holarctica] Number of unique spectra: 6 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 5 
Protein molecular weight (Da): 69165.5 AA Coverage: 8.57% 
Protein 
identification 

























100.00% ALEEAFAPIAQK K A 95.00% 1.28 0.317 5.43 1287.69 592 603 
100.00% FDLADIPPAPR R G 95.00% 0.951 0.259 6.15 1211.64 459 469 
100.00% FHDLVTAR K N 95.00% 1.64 0.35 2 958.51 531 538 
100.00% IIGIDL K G 95.00% 1.43 0.229 0 643.4 4 9 
100.00% KEEDVVDADFEDVEDDKK K - 95.00% 1.84 0.167 6.68 2124.95 625 642 
 
Protein accession number: gi|89255740 Number of total spectra: 4 
Protein name: pyruvate dehydrogenase, E1 component [Francisella tularensis subsp. holarctica] Number of unique spectra: 4 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 4 
Protein molecular weight (Da): 100253.9 AA Coverage: 3.36% 
Protein 
identification 





















100.00% HIVPITVDESR K T 95.00% 0.82 0.295 5.48 1265.69 520 530 
100.00% ITAEQLENFR R K 93.20% 0.928 0.148 8.51 1220.63 158 167 
100.00% TFGMEGLFR R Q 95.00% 0.81 0.371 5 1057.51 531 539 
 
Protein accession number: gi|89255700 Number of total spectra: 3 
Protein name: Chaperone Hsp90, heat shock protein HtpG [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 72357.1 AA Coverage: 3.82% 
Protein 
identification 





















99.80% FWDSFGQVLK K E 95.00% 1.29 0.33 3.68 1226.62 375 384 











Protein accession number: gi|89256014 Number of total spectra: 3 
Protein name: hypothetical protein FTL_0617 [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 16792.1 AA Coverage: 13.7% 
Protein 
identification 





















99.80% ILELEMSGIVR K Y 95.00% 0.91 0.41 1.85 1275.7 18 28 
99.80% SIILEEYAR K K 80.10% 1.07 0.11 1.92 1093.59 117 125 
 
Protein accession number: gi|89255668 Number of total spectra: 2 
Protein name: elongation factor G (EF-G) [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 77712.4 AA Coverage: 4.12% 
Protein 
identification 






















99.10% FVDEVVGGVVPK K E 95.00% 0 0 4.4 1244.69 536 547 
99.10% YLEGGELSEDEIHQGLR K A 81.40% 0 0 1.82 1944.93 237 253 
 
Protein accession number: gi|89255549,gi|89256480 Number of total spectra: 2 
Protein name: intracellular growth locus, subunit B [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 57901.5 AA Coverage: 3.76% 
Protein 
identification 





















98.90% DLSEITHIK K S 77.20% 1.03 0.0517 1.72 1055.57 209 217 
98.90% SFEALLEHPR K Y 95.00% 0.975 0.345 5.38 1198.62 218 227 
 
Protein accession number: gi|89257160 Number of total spectra: 2 
Protein name: 30S ribosomal protein S1 [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220620 – M1 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 61653 AA Coverage: 3.06% 
Protein 
identification 





















98.60% ISLGIK R Q 72.00% 1.07 0.243 0.201 630.42 255 260 





Protein accession number: gi|89256983 Number of total spectra: 15 
Protein name: Chaperone protein, groEL [Francisella tularensis subsp. holarctica] Number of unique spectra: 13  
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 10 
Protein molecular weight (Da): 57385.4 AA Coverage: 27.2% 
Protein 
identification 



























100.00% ALDGLTGENDDQNHGIALLR K K 95.00% 0 0 7.36 2122.05 425 444 
100.00% AVTAGMNPMDLK K R 95.00% 1.26 0.304 4.96 1247.61 106 117 
100.00% DLLPILEGVSK R S 95.00% 0.893 0.424 3 1183.69 232 242 
100.00% EAAPAMPMGGGMGGMPGMM K - 95.00% 1.46 0.349 -0.532 1860.68 526 544 
100.00% EIELEDKFENMGAQIVK K E 91.00% 1.47 0.232 1.32 1993 59 75 
100.00% LEETNMEHLGTASR K V 86.50% 0 0 1.96 1603.74 309 322 
100.00% LSGGVAVIK K V 83.90% 1.42 0.225 1.17 843.53 372 380 
100.00% MITTEAMIGEIK L E 95.00% 1.82 0.426 0 1352.68 514 525 
100.00% QVLFSDEAR K A 92.70% 0 0 2.25 1064.54 5 13 
100.00% TADVAGDGTTTATVLAQALLTEGLK K A 95.00% 0 0 8.19 2417.28 81 105 
 
Protein accession number: gi|89256512 Number of total spectra:16 
Protein name: Chaperone protein dnaK (heat shock protein family 70 protein) [Francisella tularensis subsp. holarctica] Number of unique spectra: 13 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 8 
Protein molecular weight (Da): 69165.5 AA Coverage: 17.4% 
Protein 
identification 



























100.00% ALEEAFAPIAQK K A 95.00% 1.02 0.269 4.38 1287.69 592 603 
100.00% FDLADIPPAPR R G 95.00% 0 0 5.23 1211.64 459 469 
100.00% FESLVSDLVMR K S 95.00% 1.55 0.383 4.72 1295.67 307 317 
100.00% FHDLVTAR K N 95.00% 2 0.476 2.04 958.51 531 538 
100.00% KEEDVVDADFEDVEDDKK K - 95.00% 3.16 0.425 9.33 2124.95 625 642 
100.00% MAPPQVSAEVLR K K 95.00% 0 0 2.89 1297.69 112 123 
100.00% SDITEVLLVGGQTR K M 95.00% 0.568 0.219 6.12 1487.81 334 347 


















Protein accession number: gi|89257160 Number of total spectra: 10 
Protein name: 30S ribosomal protein S1 [Francisella tularensis subsp. holarctica] Number of unique spectra: 9 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 6 
Protein molecular weight (Da): 61653 AA Coverage: 15.3% 
Protein 
identification 

























100.00% AFENNETVLGK K I 95.00% 1.29 0.414 4.42 1221.61 101 111 
100.00% AVSIGQEVEVIVLELDADNHR K I 76.50% 0 0 1.68 2306.2 321 341 
100.00% EGIEGLVHTSEMDWTNK K N 95.00% 1.51 0.187 2.28 1945.9 298 314 
100.00% GGYTMDVEGLR R A 95.00% 0.99 0.33 4.37 1197.56 118 128 
100.00% IIEATVVSIDK K E 95.00% 2.11 0.58 2.15 1187.69 23 33 
100.00% VEQMTPTTLGDLIK K E 85.40% 1.03 0.0678 1.92 1545.82 537 550 
 
Protein accession number: gi|89255549 Number of total spectra: 10 
Protein name: intracellular growth locus, subunit B [Francisella tularensis subsp. holarctica] Number of unique spectra: 8 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 5 
Protein molecular weight (Da): 57901.5 AA Coverage: 9.49% 
Protein 
identification 





















100.00% ALEQEWLK R V 93.80% 1.16 0.182 2.54 1016.54 99 106 
100.00% DLSEITHIK K S 95.00% 0.964 0 2.77 1055.57 209 217 
100.00% KEELQYDFER K N 95.00% 0.859 0.133 3.05 1356.64 127 136 
100.00% NIDFDVSDDASK K V 95.00% 1.4 0.297 5.72 1325.59 28 39 
100.00% SIISNDEFR N A 95.00% 1.19 0.453 0 1080.53 90 98 
 
Protein accession number: gi|89257020 Number of total spectra: 8 
Protein name: elongation factor Tu (EF-Tu) [Francisella tularensis subsp. holarctica] Number of unique spectra: 7 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides:4 
Protein molecular weight (Da): 43372.2 AA Coverage: 15.7% 
Protein 
identification 

























100.00% GVVNVGDEVEVVGIRPTQK R T 95.00% 1.51 0.487 2.06 1995.09 235 253 
100.00% IVELVQAMDDYIPAPER K D 93.80% 1.02 0.205 3.62 1958.99 189 205 
100.00% MTITLINPIAMDEGLR K F 95.00% 1.82 0.344 9.51 1787.94 359 374 









Protein accession number: gi|89256792 Number of total spectra: 2 
Protein name: Peroxidase/catalase [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 81211.6 AA Coverage: 4.81% 
Protein 
identification 

























99.90% WTASPVDLIFGSNSELK K A 95.00% 1.82 0.453 2.13 1863.95 676 692 
99.90% YTQEFYNNPEEFKEEFAK K A 95.00% 1.33 0.268 4.96 2313.03 379 396 
 
Protein accession number: gi|89255970 Number of total spectra: 3 
Protein name: hypothetical protein FTL_0572 [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 51961.4 AA Coverage: 5.25% 
Protein 
identification 





















99.80% ANLDIVGLK K T 95.00% 2.12 0.462 2.96 942.56 393 401 
99.80% SLTTGFGNLSGLLPIK K T 95.00% 0 0 4.5 1617.92 216 231 
 
Protein accession number: gi|89256632 Number of total spectra: 3 
Protein name: outer membrane associated protein [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 41242.4 AA Coverage: 5.36% 
Protein 
identification 





















99.80% GFGYNDTLGGIHK K S 95.00% 0 0 4.5 1378.68 360 372 














Protein accession number: gi|89255702 Number of total spectra: 2 
Protein name: NAD(P)-specific glutamate dehydrogenase [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220623 – M2 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 49141 AA Coverage: 8.91% 
Protein 
identification 

























SARLSWSAEEVESK K L 92.90% 0 0 2.27 3135.5 372 402 
99.70% FLGFEQVFK K N 95.00% 0 0 3.52 1114.59 108 116 
           Protein accession number: gi|89257020 Number of total spectra: 41 
Protein name: elongation factor Tu (EF-Tu) [Francisella tularensis subsp. holarctica] Number of unique spectra: 36 
Fraction MS/MS sample name: 8220630 - M7 (5g) Number of unique peptides: 14 
Protein molecular weight (Da): 43372.2 AA Coverage: 41.6% 
Protein 
identification 



























100.00% ELLDQYEFPGDDTPVIMGSALR R A 95.00% 1.55 0.371 8.66 2466.19 156 177 
100.00% GEAGDNVGILVR R G 95.00% 1.33 0.34 3.48 1199.64 269 280 
100.00% GITINTSHVEYESPNR R H 95.00% 2.45 0.433 6.27 1816.88 60 75 
100.00% GVVNVGDEVEVVGIR R P 95.00% 1.65 0.474 0 1540.83 235 249 
100.00% GVVNVGDEVEVVGIRPTQK R T 95.00% 0.966 0.371 2.43 1995.09 235 253 
100.00% HTPFFK R G 95.00% 1.24 0.335 0.523 776.41 320 325 
100.00% INPIAMDEGLR L F 95.00% 1.5 0.378 0 1228.64 364 374 
100.00% IVELVQAMDDYIPAPER K D 95.00% 0 0 5.36 1958.99 189 205 
100.00% IVVFLNK K C 77.50% 1.4 0.229 0 832.53 131 137 
100.00% MTITLINPIAMDEGLR K F 95.00% 0 0 6.55 1787.94 359 374 
100.00% PQFYFR R T 95.00% 1.22 0.418 0 857.43 329 334 
100.00% TTDITGAVELPEGVEMVMPGDNVK R M 93.20% 0 0 2.34 2502.21 335 358 
100.00% TTLTAAITK K V 94.70% 1.14 0.265 1.92 919.55 26 34 













Protein accession number: gi|89257155 Number of total spectra: 3 
Protein name: cell division protein [Francisella tularensis subsp. holarctica] Number of unique spectra: 3 
Fraction MS/MS sample name: 8220630- M7 (5g) Number of unique peptides: 3 
Protein molecular weight (Da): 39727.4 AA Coverage: 10.8% 
Protein 
identification 

























99.90% EAAEAAISSPLLEDINLDGAK R G 95.00% 0 0 3.28 2127.08 238 258 
99.90% ILQIGTNLTK N G 77.50% 0.923 0.417 0 1100.67 57 66 
99.90% VTVVVTGIEK K V 95.00% 1.51 0.526 1.82 1044.63 308 317 
 
Protein accession number: gi|89257060 Number of total spectra: 2 
Protein name: ATP synthase alpha chain [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220630- M7 (5g) Number of unique peptides: 2 
Protein molecular weight (Da): 55520.1 AA Coverage: 4.87% 
Protein 
identification 





















99.80% ILEVPVGEALLGR R V 95.00% 1.67 0.417 5 1365.81 94 106 
99.80% VVDALGNPIDGK R G 95.00% 1.6 0.543 5.07 1197.65 107 118 
 
Protein accession number: gi|89256983 Number of total spectra: 2 
Protein name: Chaperone protein, groEL [Francisella tularensis subsp. holarctica] Number of unique spectra: 2 
Fraction MS/MS sample name: 8220630- M7 (5g)  Number of unique peptides: 2 
Protein molecular weight (Da): 57385.4 AA Coverage: 5.7% 
Protein 
identification 

























99.80% ALDGLTGENDDQNHGIALLR K K 95.00% 0 0 2.62 2122.05 425 444 
99.80% DLLPILEGVSK R S 95.00% 0.612 0.118 3.52 1183.69 232 242 
 
